Remember that the "rare" frequency of adverse reactions stated in
the pharmaceutical package inserts is usually always grossly
underrated. The statistics provided by the manufacturers are a gross
manipulation of biased clinical trials, and are totally unreliable. For a
better assessment of your chances of getting seriously ill, consider
the table above instead. The recent experience with the U.S. postal
workers (treated with up to 60 days of ciprofloxacin) presents figures
very similar to those in table 1.
We have talked with nearly 50 people who thought that their
quinolone’s treatments had been successful and without any adverse
effect that reported having had their first time of severe bouts of
tendinitis or neurological problems a few weeks or months after the
quinolone treatment and therefore had not linked them with the drug.
The same can be said about neurological disorders. Taking into
consideration all the facts, nearly all of them now believe that que
cipro or levaquin they took is the cause of their insomnia, peripheral
neuropaties and musculoskeletal problems.
Observation:
For long or high dose treatments, the adverse reaction rate reach 100% of
patients. Many people are unaware that their illness is a manifestation of
quinolone toxicity.
There are persons that after one single pill develop a very acute
reaction that normally matures into an intermediate reaction (see
later) that lasts for 2 years on average. That should be studied by
scientifical groups because perhaps it would give some clues in the
search for an understanding of this disorders.
WHY HAS THIS REPORT BEEN WRITTEN
There is little or no medical information publicly avalaible via the
internet for the general population that deals with the practical side
of adverse reactions to quinolone antibiotics.
The only real information avalaible to date come the support groups
sustained by sufferers. (We strongly recommend visiting the
webpages www.fqresearch.org, www.drugvictims.org and
www.medicationsense.com ) (Those sites belong to their owners and do
not have any relationship with the authors of this report).
Nearly all the medical investigations in progress are not
comprehensive. The researchers in charge have a sheer lack of
knowledge about the real and true facts of this syndrome. Many
investigations are very superficial, nearly anecdotal, and only look
after a publishable paper, so that statistics of activity in the scientific
group remain high in the annual report. There are myriad scopelimiting
articles, all of which have contributed to extensive data, plus
many, many instances of scientific evidence supporting the great
damage that quinolones inflict upon people, but there is not a single
comprehensive study about the adverse effects caused by
quinolones.
No consistent clinical studies can be found that put the real figures of
adverse effects where they really are. There is not a single study that
shows the true extent of the damage caused by these antibiotics.
There are multiple causes for this lack of proper investigation:
.. The pressure exerted by drug manufacturers, the propaganda
they spread in medical circles, and the counter-studies that they
promote, most of which are unscientific creations of well paid
doctors that show “evidence according to their personal
experience" of maximum beneficial activity of the antibiotic
and their “negligible” adverse effect profile. We can even see
irresponsible and badly educated doctors prescribing and
recommending quinolones for children, when currently there is
overwhelming evidence that quinolones cause lesions of
extreme severity in inmature persons.
.. The delayed onset of symptoms is perhaps the most important
fact that is universally ignored by doctors. Many researchers
only monitor patients while they are on the medication and in
some isolated cases "up to a month later.” The vast majority of
disorders appear up to a year and a half later and are therefore

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
4/32
never linked with the real cause.
.. The lack of knowledge and preparation of the doctors that
prescribe them and the aspect that doctors nearly always dismiss
their patient’s complaints, and their refusal to admit any link
between the severe and long lasting pathologies and their causal
agent: the quinolones. The ignorance of doctors about the
toxicity of quinolones is simply appalling, irrational and
unjustifiable. Many doctors are handing out lifelong misery to
their patients and destroying their lives forever.
This report will help the non-medical population know more about
the true and real-life nature of quinolones. It can also be a call for the
caring doctor to promote a more critical approach and perform
unbiased professional research prior to prescribing quinolones.
We need to convince the medical class that:
.. Until better antibiotics are developed, a defectively designed
drug like a quinolone antibiotic should be restricted to
emergency, or life or death cases, but never used as a first line
of treatment. Quinolones are not an antibiotic in the traditional
sense, but a toxic chemotherapeutic agent, with very severe and
long-lasting adverse effects.
.. Thousands of affected people need help, and adequate research
is urgently needed in order to determine the mechanisms by
which these drugs cause their damage, and how to limit their
effects.
It is a shame that patients and victims once again have to write
reports like this, placing themselves years ahead of their doctors. In
ten years time the essential information contained in this report is
already common knowledge for thousands of persons, it will be
"discovered" by the medical class and then become accepted
knowledge. Too late for too many. Is this the medical class that we
deserve?
Reminding:
Half of the quinolone antibiotics marketed in the last twenty years have
been withdrawn from the market because of its great toxicity.
HOW HAS THIS REPORT BEEN WRITTEN
We have spent five years studying the floxing syndrome (QTS),
especially from the point of view of severe neuropaties, muscular
and joint disorders, with specific emphasis on the healthy, young,
active and athletic population.
We have challenged ourselves with blind trials using placebos and
active agents but always stayed away from potent drugs or
supplements. We have kept detailed diaries for years with tens of
thousands of entries recording ongoing symptoms and our attempts
at regaining basic movement, fitness, and athleticism. We have
probed and pushed ourselves through pains, endurances, and tests of
many kinds, varying as few factors as possible in each trial, so that
results could be of use. We have had more than a hundred MRIs
(magnetic resonance image), dozens of CATs (computerized axial
tomography), plain radiographs, three phase gammagraphies,
dopplers, echographies, electromyographies, nerve conductivity
tests, ultrasound tests, and hundreds of blood, urine, stool, and hair
tests along with many other diagnostic tests as well as a few
biopsies.
We have talked to hundreds of people suffering from this syndrome.
We have used logical methodologies to draw most conclusions.
Obviously, from observation, repetition and comparison alone, we
cannot aim to discover the mechanism of damage, or the elusive
clues for a healing protocol.
But, all in all, we, as many others, have demonstrated once more and
beyond any doubt, the extensive and devastating effects of quinolone
antibiotics and the unethical behaviour of the FDA and other western
agencies that are dominated by the manufacturer's lobbies who
routinely do not protect the people's health as they should, resulting
in the increase of financial profit for the laboratories and
pharmaceutical companies.
ARE YOU POISONED BY A QUINOLONE
ANTIBIOTIC?
If you have taken a course of any quinolone or fluoroquinolone
antibiotic (Cipro, Levaquin, Floxin, etc…) you have been chemically
poisoned. Depending on individual conditions, and the dosing and
lenght of the treatment, the intoxication will range from very mild
and asymptomatic to very severe and disabling.
In a minority of cases the, reaction is noticed immediately by the
patient. In a vast number of cases, most symptoms, or at least the
most severe ones, emerge weeks or months after the completion of
the quinolone treatment.
Many people can take a 7-day course of quinolone antibiotics
without perceiving any adverse effects. Their cartilage, tendons,
nerves and small veins and arteries have been directly damaged but
not enough to make them symptomatic. That is the case of many
sedentary people who deeply damage their joints as a result of
repeated but short courses of quinolones. But the fact remains
unknown to them since they are asymptomatic, and they do not use
their joints beyond the pain threshold. Later in life, it manifests as
early osteoarthritis, collagenous deterioration, or nervous system
failures. In any case, this paper is not intended for these people.
Many of us were healthy young athletes in perfect health with solid
rock knees and hips prior to taking quinolones but now have become
crippled persons, with our cartilages half destroyed, our eyes barely
functional, our bodies aching since several years ago and our whole
lifes stolen from us by a medical class that now turn its back on us.
For those that have developed symptoms like the ones described
later, first of all, they have to check if they have ingested any
quinolone antibiotics during the last three or four years. The damage
caused by the quinolone antibiotics becomes evident at a point in
time that ranges between the moment of the treatment itself and up
to eighteen months later. If your symptoms fit with any of the
cathegories listed later in this article, and you have taken
fluoroquinolones in the past, then a quinolone induced intoxication
might well be behind many or all of your recent physical problems.
This report could help assist you in getting a diagnosis.
SOME MEDICAL TERMS AND INFORMATION
The report has intentionally a non medical character. However, it is
necessary that you become familiar with a few technical facts
regarding the floxing syndrome. Some are exposed along the report,
when they are needed. A brief introduction to the general aspects of
an adverse drug reaction is included here.

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
5/32
The terms drug allergy, drug reaction and some euphemisms
(hypersensitivity, intolerance) are often used interchangeably. If we
take into account the inmune response of the patient, drug allergy
can be restricted to the reaction in which special antibodies of the
IgE type are massively released. This report does not cover allergic
reactions.
Like many other drugs, quinolones can cause an inmunologic type I
reaction, plus many noninmunologic primary pharmacologic side
effects (insomnia, restlessness, coffee intolerance) and secondary
pharmacologic side effects (thrush, leaky gut). They can also interact
negatively with many drugs. But their distinctive actions are
probably due to their direct toxicity and the subsequent inmunologic
reaction.
Drug reactions can be classified as follows:
-table 2- TYPES OF DRUG REACTIONS

-table 3- TYPES OF INMUNE REACTIONS

In most cases, there are not markers that can confirm a diagnosis, so
all serum (blood) parameters can be normal and still be suffering
from a very severe and incapacitating reaction. Only a very
specialized and very unnacessible tissue biopsy can confirm the
problem. Therefore, most diagnostics are stablished upon clinical
symptoms. In principle, the fluoroquinolone syndrome can be
classified as a TYPE III inmunological reaction, with an added
noninmunological TOXICITY.
One thing is clear: re-exposure to quinolones, after having been
floxed previously, poses a very high health risks on the patient.
Persons that become floxed twice have the worse prognosis
(expected outcome). Many people with moderate reactions to
quinolones are later exposed again to another round of the same
antibiotics by their doctors after dismissing their complaints about
pains and disorders associated to the antibiotic. The outcome is
frequently a severe reaction that lasts 3 to 5 years and permanent
lesions.
WHAT KIND OF DAMAGE DO QUINOLONE
ANTIBIOTICS CAUSE?
This class of antibiotics has very characteristic ways of causing
lesions:
.. they damage the central and peripheral nervous systems
.. they damage small veins and arteries (vascular disorder of the
vasa vasorum and vasa nervorum)
.. they impair the rebuilding and repairing capacity of tissues,
specially connective-collagenous
.. they chemically destroy important structures, like cartilage
There are many other mechanisms of quinolone assault on the
human body (for instance, liver, kidney, pancreas and heart reactions
all of which can be fatal), but they are not the focus of the present
report.
Important fact:
Pain and disability caused by quinolones is very long lasting and affects
many parts of the body. In favourable cases recovery takes several
months to years. In severe reactions pain and lesions can last for life.
HINTS AND CLUES THAT MIGHT SAVE YOUR
LIFE
Perhaps you have taken quinolones in the past and you think that
they worked well and that you did not react negatively to them.
Check the following subtle symptoms and the usual interpretations
that people make of them.
.. You had a strange bout of tendinitis, for instance in the outer tip
of the hip, normally diagnosed as trochanteric bursitis caused by
tight belts or resting on you side. The same applies to other
areas of the body, like the elbow (epicondylitis) diagnosed as an
overuse of your tennis racquet or gardening practices, but you
remember that you had never had it before.
.. It takes you longer to recover after exercise. It is not alarming
and you have not paid much attention to it.
.. You sleep worse than before; it seems normal as you have a lot
of pressure at work.
.. From time to time you have some small throbbing pains in
different parts of the body. They last only for a few seconds, so
there is nothing to worry about it.
.. It is strange but you have occasional twitching in an eyelid, or
any other part of the body. It is not painful.
.. Some nights you feel some mild itching migrating along your
body. One brief itching here and another there. It is more
intense in the scrotum or groin. Instead of identifying it as a
peripheral neuropathy you conclude that it must be your clothes
or the new soap brand, that is more irritating.
.. You feel some stiffness, especially in one or both legs, but it is
normal because you are getting older.

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
6/32
.. You do not tolerate coffee as well as before.
.. Your memory is not as good as it used to be. The cause may be
too many things to think about and much stress. And you are
no longer a young person.
.. There is an urge to urinate when the bladder is partially full.
Most urologists think that is due to a dysfunction associated to
benign enlarged prostate but in reality is a neurological deficit
caused by the prescriptions of quinolones that they gave you.
If you have experienced some of these symptoms since you took
your first quinolone, perhaps you have reached your first threshold
of tolerance that -once surpassed- can result in the destruction of
your life soon thereafter if you take more quinolones.
WHAT ARE THE MAIN SYMPTOMS OF BEING
POISONED BY A QUINOLONE?
For a complete list of symptoms see later in the report. A strong
reaction generates some 30 to 50 symptoms. In some cases adverse
reactions appear right after the ingestion of the antibiotic. In
intermediate and severe reactions you may start with a few
symptoms and as time passes new and debilitating symptoms arise,
specially around the second, sixth and ninth month’s marks. And in
many cases of young, very healthy and active people, the worst
lesions emerge progressively up to eighteen months or more after the
cessation of the drug (we have deducted it beyond any doubt from
various cristal-clear cases plus several rechallenges with quinolones).
Here we include the most easily recognizable and common.
Joints and muscles-neuromotor:
.. Arthralgias (pain in joints)- especially the Achilles, plantar
fascia, ankles, knees, hips, elbows, shoulders, wrists and others.
They start as early as during the antibiotic treatment, in which
case some times the floxie becomes bedridden or unable to walk
or drive for several months, requiring a wheelchair or crutches.
In other cases arthralgias show mildly at the beginning and their
intensity increases to its maximum intensity up to a year and a
half later. In this type of delayed reaction, some six hours after
strenuous exercise the symptoms may be present as acute pains
that can be excruciating if the limit of tolerance is reached. This
limit consists of the maximum exercise that a given body can
tolerate before its impaired repairing capacity is overwhelmed
by the physical demands. For the average floxed athlete, this
limit is much lower than it was before the quinolone
intoxication.
.. Acute tendinitis not responsive to conventional treatments. This
type of tendinitis is very acute at times, requiring
immobilization, and is nearly always triggered by a level of use
that was normal in the prefloxed state, or normal daily use. The
tendinitis does not respond to anti-inflammatory medication,
which in fact, can make the symptoms worse. Sometimes the
tendinitis migrates within a joint and from one joint to others. In
the first stages of the floxing, the tendinitis is predominantly
enthesitis, which is inflammation of the insertions of muscles
and tendons into the joints. In many cases they end up in
partially or fully ruptured tendons (achilles, shoulder rotators,
wrists flexors). It is a class effect of all quinolones, in other
words, all these antibiotics are very toxic for all the tendons in
the body, for everybody. For every one the quinolones cause
small and multiple lesions in the tendons, that eventually
rupture in those people unlucky enough having weak tendons,
having taken corticoids, having preexisting vascular problems
(prediabetics) or being magnesium deficient.
.. Arthritis-like symptoms. Many symptoms resemble those of
rheumatoid arthritis and other autoimmune diseases, but are
always sero-negative and with a different pattern of clinical
symptoms.
.. Osteoarthritis-like symptoms. Joints usually start to make a lot
of noise.After the intoxication, and with time, healthy cartilage
becomes softened and erosion takes place, and the illness
presents itself as a true clinical osteoarthritis. Knee cartilages
are specially targeted by quinolones, with a very high incidence
of torn menisci (inside the knee). There are many cases of
complete destruction of previously healthy joints and the patient
has to be submited to very invasive surgical procedures and or
total joint replacement. The most damaged cartilages are the
more weight bearing ones: knees, hips and low spine.
.. Increased stiffness after exercise. It takes longer to recover
from exercise, and there is a clear loss of flexibility. Soreness in
many muscles, specially legs and shoulders, with also a
predilection for the neck.
.. Very slow recovery from impacts and blows. Whenever the
affected person is hit in athletic or daily activities, the flesh
takes much longer to recover from the pain, along with
hemorrhaging and inflammation. Dark veins, hemorraghe-like
patches under the skin.
.. The skin (and other collagenous tissues) loses nearly all
capacity of recovery. A cut on the skin near an affected joint
leaves a pink scar for many months afterward whereas it would
have become unnoticed in prefloxing state.
.. Cold feet and hands.The presentation resembles Raynaud's
syndrome. In many severe cases several phalanges of fingers
turn numb or close to frozen with cold conditions that did not
cause any trouble before the floxing. Loss of sensitiviness in
hands and feet.
Central and peripheral nervous system and systemic:
.. Brain fog, depression, depersonalization, short term memory
loss, lethargy. Slurred speech. Unability to speak fluently.
Forgetting words, getting stuck in the middle of a sentence.
Some are caused by the insomnia but it is mainly a neurological
lesion of the brain.
.. Twitching, trembling, throbbing, pins and needles sensations,
and pulsating pains in muscles and joints are the hallmark of
this disease; especially in the lower legs (ankles, Achilles,
calves, and knees), but can manifest all over the body.
Fasciculations (visible crawling under the skin) of muscles, due
to denervation. Twitching is manifested earlier in eyelids and
the triangle on the back of the hand placed between the thumb
and index finger.
.. Insomnia, very acute and difficult to tackle with. Without the
aid of herbals or drugs, severely floxed people may suffer
extreme insomnia (2 to 3 hours of unresting sleep a day) for
more than two years. Over-reaction to caffeine. Anxiety,

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
7/32
depression, pre-seizure state. During some part of the floxing
most people experience anxiety and panic attacks (awakening
amidst strange nightmares with fear and a feeling of dying),
especially at night or when falling asleep. Headaches, especially
unilateral, or affecting one side only.
fig.1. -frequency of musculoskeletal disorders in severe reactions-

.. Vision problems. Diplopia (double vision) and other focusing
problems. Floaters (darkened points, spots, cowebs, strings..)
moving in the vitreous of the eye, flashes (small or big
wandering lights crossing your sight, some quickly others
slowly, also called ziggies if they don’t exhibit a stright path),
brilliant lights, halos and watery curtains, acute photofobia,
complete or partial loss of vision (transitory, but lasting up to 6
minutes of absolute blindness seing just solid white), blank
points, eye pain, oculaar pressure, blurred vision. Quinolones
cause degeneration of the retina, specially the outer margins.
Vision damage reach its peak about two to six months
postfloxing. Vision damages caused by quinolones have a high
ratio of irreversibility. Severe reactions have nearly always
associated some degree of damage on the vision, that is
invariably assesed by the patients as very disabling. We have
seen so many, really a great many, cases of irreversible damage
of vision, or lesions not cured by the 5th year mark, and the
distress inflicted on the sufferers, that this would on its own be
enough cause to withdraw all the quinolones from the market
for primary care treatments.
.. Diminished erectile function (semi-impotence). Difficulty to
reach hard erections. Decreased sex drive (libido) both for men
and women. Can last up to three years in severe reactions for
young people, very healthy and active sexually prefloxing.
.. Digestive problems. The quinolones damage all the nervous
network governing the intestines. Alteration of intestinal
movements. Intolerance to foods and many compounds. Bad
reactions from defectively degraded foods. Inability to absorb
some nutrients, specially minerals. Weight loss. Destruction all
of the flora and proliferation of bad fungi.
.. Violent rectal spasms, that may cause fainting. Pains of every
sort and intensity in everypart of the body: skull, lower head,
neck, jaw, shoulders, arms, back, hips, legs, ankles, fingers and
toes.
.. Trembling of a limb after sustaining tension with the muscular
groups of that limb. For instance, trembling of the leg after toeraising
for a while, or an inability to write steadily after holding
a heavy load with that hand.

fig.2. -frequency of systemic disorders in intermediate and severe reactions-
.. Heart palpitations and arrythmias, some times life-threatening.
A serious heart condition called prolongation of the QT-interval
is a class effect of all the quinolones, showing once more that
they are very defective drugs. Skipped heart beats, irregularities,
severe poundings. Some times floxies require the implantation
of pacemakers. Many thousands of people dye from heart
attacks that are not of an infarction kind but cardiopathical,
caused by deffective nerve signals. Nearly all of them are
caused by toxic compounds, like work environment hazards, or
medications, among them the quinolones.
.. Alterations of liver, kidney and pancreas enzymes and
parameters. While taking quinolones the cholesterol and
tryglicerides skyrocket up to three times their normal values, to
return to normal range in a few weeks. Quinolones also provoke
hypo and hyperglycemias as a class effect. The quinolones
accelerate the progression towards full diabetes of those
individuals with a unrecognized precondition.
Autoinmune like responses:
The main symptoms of a quinolone poisoning resemble those of
some autoimmune disorders because in acute intoxications they
cause a type of small vessel vasculitis with neurological dysfunction:
.. Dry eye, dry mouth, dry sinuses and a shift towards dry skin.
Dry eye can be measured with moisturing stripes rendering null
values in severe reactions. Sticky, gritty eyes. Dry mouth,
specially at night or when taking any vasodilator. Dry sinus
causes a lot of infections that are opportunistic due to the
compromised inmune system of the severe floxies.

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
8/32
.. Neurological pain that migrates throughout the body; muscular
and joint pains.
.. Cycling or relapsing of symptoms. Causing intolerance of
certain foods. Increased sensitivity to chemicals, especially to
quinolone-tainted foods (poultry, beef).
.. Many symptoms that resemble fibromyalgia, multiple sclerosis,
lupus erythematosus, rheumatoid arthritis, reactive arthritis,
vasculitis, AIDS and other diseases.
.. Skin rashes, on hands, feet, and other areas.
WHICH KIND OF ADVERSE REACTION TO
QUINOLONE ANTIBIOTICS ARE YOU SUFFERING
FROM?
Reactions to drugs vary among individuals. But there are some very
common patterns of bodily responses to quinolone intoxication.
From the study of many cases we have concluded that it is useful to
envisage a simple scale of severity of the reactions. According to it
you can have a mild, intermediate or severe reaction. Obviously
there are not clear delimitations between them and every reaction is
unique and personal, but if you can assess to which kind you could
be fitted into, you will acquire a more precise diagnosis and will be
able to address your problem accordingly.
Many people suffer acute reactions during the first days. Eventhough
they get very scared the acuteness has no direct relation with the
severity of the reaction as a whole. You will only be in a position of
making a judgement on the severity of your QTS after a few months
since the cessation of the drug, when you line up the whole list of
symptoms, their intensity and their evolution.
If your suffer a mild reaction you can expect a good recovery in 4 or
6 months. For a intermediate reaction is typical a convalescence of 1
to 2,5 years with a diminished but aceptable life quality. Severe
reactions mean a miserable living for at least 3 years plus another 2
years to get acceptable pain levels, ending up with permanent lesions
and life limitations. This article focuses primarily on severe
reactions.
Check whether you fall into one of the following categories. There is
not a clear-cut boundary between severe, intermediate and mild
reactions. On top of that everyone is different and can have, for
example, 20 symptoms belonging to the intermediate reaction level,
and 1 or more with a greater intensity, typical of a severe reaction.
-table 4- INTENSITY OF SYMPTOMS. LEVELS OF REACTION

The whole list of the adverse reactions to a typycal quinolone is
included later on this report.
Summarizing:
Many reactions are mild and INTERMEDIATE and heal in a few months or
years with no serious sequela.
For everyone there is an extremely high risk of experiencing a severe
reaction for doses of fluoroquinolones of 1.500 mg a day for 7 days
or 1.000 mg for 2 months. Severe reactions are very distinctive
because they are extremely long lasting and feature many permanent
lesions, specially in the 4 following groups:
.. neuropathies, including peripheral, central (insomnia, ...) and
autonomic (heart, intestines, ..)
.. dry damages (eye, sinus, ears, skin, mouth)
.. cartilages destruction, joint and muscle pains
.. vision lesions (floaters, blank points, retina degradation)
ALLERGIC REACTION
(It is a complete incompatibility between your body and the drug)
If you are allergic to quinolones, as soon as you take a few pills or
even one single dose, your body reacts negatively and feel one or
more of the very noticeable side effects listed in the package insert
and in this report, that normally force you to stop the treatment
inmediatly.
This is a type of allergic reaction or anaphylactic shock and is not
covered by this article.
SEVERE REACTION
(FULL IMPACT. Severe toxicity. Inmediate problems)
This report deals specially with SEVERE reactions. If the damage
caused by the antibiotic is extensive and deep, the athlete will
experience limiting pain as soon as he intends to exercise
strenuously during the course of a quinolone antibiotic or right
afterwards. In this situation, the athlete will experience some or all of
the following:
.. Tendinitis over different parts of the body. For an athlete, this
tendinitis is very similar to normal types but different in its
persistence and unresponsiveness to conventional treatments.
The joints most affected are the Achilles and ankle complex,
knees, wrists, shoulders, hips, fingers.
.. Arthralgias in the joints. Pain of different kinds, very frequently
migrating around a joint and then moving to other joints over
time. Pains are often very debilitating, requiring almost absolute
rest for months because patients cannot walk at all or more than
a few paces or stand up for long. Even if the patient is
functional, pains have a neurological root and can be very
intense and interfere with normal activities and prevent sleep.
These arthralgias evolve to osteoarthritis in many cases with
cartilage erosions.
.. Weird sensations in the muscles and joints, like tremors,
twitching of eyelids or any muscle in the body, pulsating pains,

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
9/32
vibrations under the skin, heat or burning sensations.
.. Vision problems. Most prominently in the form of many
floaters (dark worm or spot like) that seem to float in the
vitreous area of the eyes. Also ziggies (brilliant minute lights
that move in a zig-zag or wavy manner in your field of vision).
Curtains of watery sight in the upper part of the field of vision
that move sideways along with your eye. Waves-like in the
outer margins of the sight. Sparks (flashing lights). Photophobia
or intolerance to strong sunlight or artificial light. Difficulty in
focusing on objects, and double vision. Occasionally temporal
loss of vision. Eye pain. In many cases, some very worrisome
implications such as dry eye syndrome are also experienced.
These problems reach their peak of intensity around the sixth
month postfloxing and last for years or become a permanent
lesion, being a marker of the likelyhood of recovery (the drier
and longer, the lesser are the chances of overall recovery).
.. Restlessness, great loss of sleep quality. Anguish and anxiety
episodes. Some times panic attacks. Intolerance (great
nervousness or increasing symptoms) to concentrated coffee
(espresso) and tea. Insomnia can last more than 3 years during
which is difficult to get more than a few hours of disrupted and
bad quality sleep. Intolerance to coffee can be present for more
than 7 years.
.. Tinnitus, or ringing in the ears. Ear pressure, usually in waves
of pressure. Hypersensitivity to normal sound. Headaches, head
pressure, mainly asymmetric.
.. Myalgias (muscular pain) all over the body, or very localized in
some parts. A strong perception that everything is not normal,
because there is not a normal recuperation after exercise, and
the individual feels achy and sick. Longer and incomplete
recovery after exercise, that leaves an ever-increasing stiffness
of joints and an aching body all over in an asymmetric fashion.
.. Heart palpitations and strange pounding and throbbing.
Skipping beats. Alterations of heartbeat. Irregular heart beats
are usually more common after eating.
.. Chest pain. Heartburn.
.. Foggy mind, drowsiness, lethargy, loss of drive and power.
Need to sleep. Tiredness and intense fatigue.
.. Strange reactions and intolerance of foods, supplements, and
chemicals. Sensitivity to parfumes, health care products and
chemicals. Taste and smell perversions. Lack of smell
sensitiviness.
.. Dry eyes, dry sinuses, dry ears, dry mouth, drier skin. These are
external manifestations of a serious lesion to all the vessels that
carry vital fluids. The same damage has been done to many
other internal organs, hence the abnormal intestinal function,
food intolerances, chemical disturbances, cycling of symptoms
and general malaise. Dry eye can have serious consequences if
not treated. Dry sinuses make you proner to get infections.
.. Neuropathies in limbs, with a lot of pain with muscle wasting
and nerve involvement. In many cases they resemble muscular
injuries. For instance, a peroneal (outer leg) nerve neuropathy
can be considered a pull in the hamstring; a peroneal nerve
neuropathy can be disguised as an ankle strain, or an overuse
syndrome and so on. These neuropathies start soon and grow in
intensity for many months. In many cases it takes several years
to get a remission of these neuropathies.
.. Skin rashes, specially in distal areas (hands, ankles). Itching, all
over the body, with little intensity, plus more intense in some
specific areas (hips for instance) when taking a hot shower, plus
itching in the groin and scrotum at night when hot. Reddish or
red-blue upper eyelids. Increase in vertical ridges in nails of
toes and fingers.
.. Weight loss, probably due to muscle destruction and atrophy
and alterations in intestinal function.
.. Abnormally cold feet and hands. Fingers close to freeze in low
temperatures that do not cause any trouble to normal persons.
Lack of feeling in some fingertips. Increase in depth of vertical
ridges in finger nails.
.. Problems with foods and drinks. Your intestines are also altered
and their permeability and ability to process foods is impaired.
If you have most of the above mentioned symptoms 9 months after
drug cessation and half or more of them are very intense, then
probably you are suffering a SEVERE reaction and this report is
specially devoted to thoses cases.
INTERMEDIATE REACTION
(MEDIUM TOXICITY. Delayed colapse)
Symptoms from a quinolone antibiotic intoxication of a lesser
intensity start with mild pains during the treatment or soon
afterwards, that are of small intensity and can even pass unnoticed.
In any case, during the first months, most of the problems are
musculoskeletal and tend to resolve without complications. But some
six to fourteen months after cessation of quinolone antibiotic
therapy, the active athlete can become suddenly prostrated and
severely affected, normally in one single joint.
This is the typical list of symptoms of a person in which the worst
adverse effects are of a musculoskeletal nature:
.. Tendinitis over different areas of the body. For an athlete, this
tendinitis is very similar to normal tendinitis but different in its
persistence and unresponsiveness to conventional treatments.
The joints most affected are the Achilles and ankle complex
(posterior tibial tendon, anterior tibialis, flexors of the toes),
knees, wrists, elbows, shoulders, hips, fingers.
.. Arthralgias in the joints. Pain of different kinds, very frequently
migrating around a joint and then moving to other joints over
time.
.. Weird sensations in the muscles and joints, like tremors,
twitching of eyelids or any muscle in the body, pulsating pains,
vibrations under the skin, heat or burning sensations.
.. Medium intensity neurological symptoms like insomnia, panic
attacks, anxiety and any light side effect included in the list at
the end of the report, plus the invisible lesions like cartilage
softening.

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
10/32
MILD REACTION
(Low level toxicity. Supposed safe reaction. Further problems)
In these cases, apparently there are no symptoms associated with the
quinolone treatment and the individual can feel no adverse reactions
after taking a quinolone prescription, especially a short one or one
with low doses. But the quinolone takes its toll and after several
treatments spaced weeks, months, or even years apart, subtle
symptoms will begin to develop, and the sufferer will probably never
link them to the antibiotic.
These symptoms will probably be: restlessness, especially at night,
brain fog, some minor twitching, increased cool hands and feet,
slower recovery after strenuous activity, increased stiffness after
exercise. And the unavoidable erosion of cartilages will be inevitably
added to the list.
In short:
Severe reactions present with intense, long lasting joint and
neuromuscular symptoms plus eye disorders and dry mucous parts.
WHICH ARE YOUR CHANCES OF RECOVERY?
As explained before, most people recover from the quinolone
intoxications. Many do not. Everyone with intermediate and severe
reactions get permanent damage although if it can be internal and it
can remain more or less unnoticed if it does not affect much their
daily lifes (cartilages, central nervous system). Some people ends up
with permanent chronic pain, physical difficulties, heart or vision
damage or many other irreversible lesions.
Therefore, if the toxicity level is not high, that is to say, if there are
little nervous and vascular systems alterations, the average person
will probably recover, albeit with the cartilages of the weight bearing
joints slightly eroded. The athlete will enter an accelerated course of
decay because his/her cartilage will not keep up. The endurance
athlete will no longer be able to perform at a decent normal level.
For instance, in severe cases photophobia resolves in some two years
on average, focusing impairments in 2.5 years, and flashies and
floaters take many years to fade off. Another indicator of the severity
of the floxing is a dry mucous condition. If you have long lasting dry
eyes, plus dry mouth and sinus, you are no doubt suffering a severe
reaction and running the risk of ending up with quite permanent
lesions.
If the toxicity level is high, the average person might eventually get a
decent daily life similar to the one he or she enjoyed before taking a
quinolone, but with some physical limitations for repetitive and
strenuous activities. The athlete will no longer be able to return to
competition in any impact sport, and in the best case he will be
capable of enjoying biking, hiking, swimming or other sports that
put little stress on the joints. Healing and recovery time until
reaching this point is more than three years on average. There is a
concerning number of cases for which recovery seems to be elusive
after five or more years after the last quinolone pill ingested. Perhaps
during the coming years we will see the confirmation of cases of
permanent disability, or lifelong pains and misery caused by
quinolone antibiotics.
The recovery and return to acceptable levels similar but lower to
previous ones will take one and a half years on average. If the
reaction is severe, pains and limitations can last 4 to 5 years on
average or be permanent.
It is summarized as follows:
-table 5- LIFE AFTER RECOVERY

The successful recovery stories of people enduring intermediate and
mild reactions are currently overrated because many people that end
up feeling normal are still far behind a complete recovery but they
cannot tell because they are sedentary. Those persons can report that
they are cured some two years earlier than the real healing takes
place. Nobody really gets out undamaged. Although it is difficult to
trace enough people long enough to get a conclusion, it is widely
admitted nowadays that many people remain symptomatic in a
permanent, irreversible manner.
Remember:
If you suffer a severe reaction, your chances of complete recovery are
lower than 40%.
Chances of recovery are predominant for the age bracket of 20-40
years. After the age of 40 recovery can take much longer. Beyond
the fifties more permanent damages are recorded. For people above
70 years old, recovery is completely unlikely in the case of severe
reactions.
Nearly all floxies can tell when they are recovering, because at a
precise point in time they experience less problems with foods
(recovery of the toxicity and neuropaties that prevent intestines and
organs from working properly), a lower level of pains, less stiffness
and soreness, more flexibility, there is a weight gain, insomnia
improves, and they feel stronger in every sense. Then some anxiety
develops in all floxies because they all see a glimpse of normalcy at
the horizon, and would like their ordeal to stop inmdiatly after long
years of suffering. But in severe floxings on average you feel some
recovery when you are half way the reaction, that is to say, at the 2,5
year mark for a 5 year recovery period. The second part of the
floxing is more compatible with a normal life (save sports or
strenous activities) but you still cannot eat freely, you get through
many cyclings, but many neuropaties and permanent lesions (vision,

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
11/32
drynesses) are still present and the floxie gets concerned about the
life lost and the perspectives lying ahead.
EVOLUTION OF FLOXING SYMPTOMS
The symptoms are listed in the above paragraphs. The evolution of
the pathology is very characteristic of this syndrome. For severe
reactions, new symptoms keep emerging for up to nearly two years
after the last pill has been ingested. The worst disorders become
apparent between months 6 to 9, but others still appear up to month
20. It varies a lot with each individual, but very typically it evolves
as follows:
SEVERE REACTION
Month 1-2: (acute phase) maximum musculoskeletal symptoms; possibly
crutches or wheelchairs needed, high level of pain, and crippling
limitations.
Month 6-9: (acute phase) maximum damage, irrespective of symptoms.
Maximum vascular damage, that affects eyes, joints, heart, ears, and so
on. Erosion of cartilages can be felt and also diagnosed by physical
examination and imaging.
Month 9-30: Increasing of the symptoms, very much affected all over. Pains
all over, with soreness, stiffness. Strong feeling that something is going
really wrong and worse. New symptoms of a toxic systemic vasculitis
(see later) may arise, like dry eye, dry sinus, and abnormal reactions to
otherwise normal infections like flu or colds that lead to a trail of deeper
symptoms. If dry eye does not develop or if it is not long lasting, the
chances of overall recovery seem to be far greater. Very intense
neuropaties in legs and other areas of the body, that can be detected in
ordinary testing. Maximum muscle pains.
Month 24-36: Cycling of symptoms. Some disorders may experience an
improvement like insomnia and some central nervous issues. Panick
attacks tend to stop. Still very sensitive to any food or suplement with
constrictive properties. A little better from myalgic pains and stiffness.
Still present exercise intolerance, dry syndromes, and vision lesions.
Month 30-38: Recovery predominant, slow progress but firm. You can feel
strong and determined and your spirit might go up too. You start to see
what permanent lesions the quinolones have caused. Less neurological
pains but still twitching, fasciculations, trembling, itching and other
similar symptoms.
Month 36-60: In roughly 40% of the cases, noticeable recovery for sedentary
people (recovery is not complete but the inactivity prevents the
endurance damage to show up). Slow recovery for active people
because strenuous exercises make symptoms to reappear, endurance is
still low, and the body is not still able to recover normally after
physically demanding activity. In the remaining 60% of the severe
cases, by month 36 people feel better than a year before but are still far
away of recovery.
From the 4th year on: depending on the individual, near complete or partial
recovery is reached. Typically irreversible damages are dry eye, dry
sinus, dry ear, dry skin, floaters, blank points in vision, some
palpitations, neuropatic pains-bearable, exercise intolerance and
occassional muscular pains.
Total recovery time: ranging from 3 to 5 years or never in some
cases that end up with different permanent lesions.
INTERMEDIATE REACTION
Month 1-12: minor musculoskeletal symptoms; limited activity, incorrectly
associated with overuse, or mechanical problems. acute phase for other
minor effects.
Month 12: (acute phase, in active, athletic people only) due to accumulated
damage, peak symptoms are reached. Collapse of a joint is typical.
There are no or very mild accompanying symptoms (vision,
neurological, etc...).
Month 12-22: Recovery predominant, relatively fast progress.
Active and athletic people will see their endurance drop a lot and
they will develop osteoarthritis early, perhaps some ten years earlier
than non-floxed people, and depending on dosage.
In MILD REACTIONS, recovery is reached between moths 4 and 12
on average. In some cases they have an acute phase of up to 3
months.
In summary, on average people tend to feel well albeit partially
recovered, according to the following timing:
.. severe reactions: 4,5 years
.. INTERMEDIATE reactions: 1,5 to 2 years
.. mild reactions : a few months
Everyone behaves slightly different to the floxing because daily
habits and personal conditions can somewhat modify the evolution
of the recovery.
CLASSIFICATION CRITERIA FOR THE LOWER
LEG
(As an example, for classification purposes, we have established a scale of
severity of the tendinitis and joint problems, used to make entries in the
research diaries).
The severity of the physiological performance of any given part of a
floxed body is graded according to its functionality. For instance,
Grade 1 corresponds to the normal state, and Grade 9 to the prerupture
of tendons.
-table 6- CIPRO INDUCED TENDINITIS

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
12/32
A floxie is constantly moving from one grade to another, depending
on the ingestion of more drugs, activity level and time elapsed since
last ingestion of quinolone antibiotics. Cycling of symptoms keeps
floxies moving up and down the scale. In many cases, grade 1 is
never recovered again, but instead a low, functional grade is
maintained.
We have used other similar tables for neurological issues when
preparing this report.
PAIN LEVELS
Pain levels experienced throughout the floxing can range from very
low to the maximum on a 10-point scale. Pains of the maximum
severity- stabbing, jabbing, tearing, and ripping, can be felt when a
joint or limb collapses neurologically. These pains are described as
higher than passing a kidney stone or rupturing a testicle, for
instance, and can completely block the affected joint. Intermediate
pains are common with mono-neuritis in legs, arms and neck,
especially at night and with some minor movements. Low intensity
pains (that correspond to myalgias) typically spread all over and
correspond to the "normal" state of a floxie: just feeling like a person
that is 40 years older than their current age. See later for more
information on neurological pains, how can affect daily life and how
little can be done to paliate them.
IMPAIRED HEALING IN THE FLOXED BODIES
This is another very distinct characteristic of quinolone disorders, of
which every doctor is unaware. Once you think your ankle is nearly
recovered from a intermediate reaction (say in grade G2), if not
enough time has elapsed since the ingestion of the drug (less than 2
years) then only a few repetitions of an exercise with your foot
against strong resistance can bring you to Grade 9. So, returning to
normal pre-floxing levels of activity is a continuously probing (trial
and error) method, not exempt of relapse and danger.
The floxed body has been depleted of nearly all of its natural healing
capacity. To function properly, the body must continuously produce
new tissue, especially cellular matrix, collagen and fibrous cells. For
everybody, the toxicity of the quinolones kills these mechanisms, in
a dose dependent manner.
So whenever you accidentally bump a part of your body, especially
the hand or foot (more distant areas and less irrigated tissues) it takes
an abnormal amount of time to recover. Small blows that in a normal
situation would take three days to heal, can take up to three months
of healing during the acute phases. A cut in the skin around the
Achilles will take the same time to close than in any other area of the
body, but ten to twenty times longer for the scar to clear off.
When the athlete approaches grades 6, 7, 8 and 9, there is a lot of
deposition of waste in the joints and under the skin. That makes the
waste adhere to the joints and worsen the symptoms. Massage helps
to remove those deposits in most cases.
During the months that follow the acute phase, both mechanisms
(healing and rebuilding) are slowly returning to normal, especially
the quality of the rebuilding, although the healing response still
cannot keep up with the requirements of our previous (pre-floxing)
level of activity. There are many scientific reports that show
ciprofloxacin impairs the healing of broken bones and connective
tissue. Being floxed is not the best time to undertake minor surgery
that could be avoided or rescheduled for later.
So, during the acute phase it is not possible to cope with strenuous or
very repetitive activities. It is normally advised to maintain some
degree of physical activity, but always testing and probing the limits,
without surpassing them.
Quinolones make it more difficult for people to recover after
exercise, and can cause them to develop a frank intolerance or
dislike to exercise. Pains and stiffness after exercise are very
characteristic of this toxicity. That is most likely due to a chemical
damage of the fascia (connective tissue) that exists between muscles
and allows them to run smoothly and independently. These lesions
can last for many years after the floxing.
TOXICITY GUARANTEED
Apparently there are not many studies of clinical significance that
provide a wide explanation regarding the high toxicity level of
quinolones. One can find medical reports suggesting that everyone
having a bad reaction to fluoroquinolones had a previously
underlying muscular disorder. We do not favor that theory. Also,
there is no validity to the claim that all people having a reaction to
quinolones have a common flaw or genetic component that make
them more prone to suffer adverse events. The medical community
will start to understand something about fluoroquinolones when they
acknowledge that these antibiotics are just plain toxic.
Many of us have apparently not had an adverse reaction to the first
three, four, ten or even twenty courses of quinolones over several
years, but later on symptoms indicative of an adverse reaction
culminate to the point where the patient is completely intoxicated
from the quinolone. Many, many young, healthy and athletic patients
just change in a short period of time from being the idyllic human
model for every drug manufacturer, to be intoxicated for many years
or life, and then are labelled as psychotic, a hypochondriac, or
diagnosed with serious neuropathies and pains that "were just lying
dormant."
That is simply not true. The fluoroquinolones are toxic from the first
milligram. Some people have body tissues that are more resistant
than others, but everybody becomes intoxicated. Each person has
two different potential thresholds of resistance to the damage caused
by quinolones:
LOWER THRESHOLD
Has been exposed above. It is delineated by strange bouts
of tendinitis, abnormally long recoveries after exercise,
less sleep and poorer quality sleep, some small throbbing
pains in different parts of the body, occasional twitching,
feeling some stiffness, decreased tolerance to coffee, loss
of memory, specially short-term.
UPPER THRESHOLD
The symptoms that you have experienced are those
corresponding to the severe reactions, intermediate
reactions and mild reactions. It is too late to expect a rapid
resolution, and according to the level of the intoxicationlong,
hard and miserable times may lay ahead.
The toxicity of quinolones acts in two preferential ways:
.. direct chemical destruction (cartilage, cellular functions
and organs).
.. mild, long-lasting or irreversible vasculitis, with

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
13/32
neuropathic after effects.
Obviously, you will not find many doctors willing to admit these two
phenomena do actually occur. But the sooner more research is
conducted in that direction, the further we will advance in terms of
understanding the problem.
The following section of the report deals with some of the most
important problems caused by quinolones.
THE VASCULAR CONNECTION
This point of the report is a hypothesis on the ultimate cause of the
floxing syndrome. We cannot aim to discover anything of medical
importance. But we can argue about some ideas that correspond well
with t our experiences, the clinical symptoms and that allow us to
favor some habits and avoid others in our daily lives, with some
basic understanding about the why and why not.
Although it is not generally accepted, we think that one of the main
damaging paths used by fluoroquinolones is vascular. There are
many scientifical papers that relate vasculitic events induced by
quinolones but they are presented as exceptional happenings.
However, the quinolones provoke unfailingly a specific sort of
vascular lesion.
Arteries are composed of 3 layers. The intima is composed of the
endothelium and underlying subintimal connective tissue. The media
is composed of the internal and external elastic lamina surrounding
the smooth muscle. The adventitia lies at the outermost area
comprised of connective tissue in which nerve fibers and vasa
vasorum (small vessels) are dispersed.
The vasa vasorum exist within the substance of the end organs.
These vasa vasorum include the capillaries, that are approximately
the size of a red blood cell and they do not have the media layer. The
very small vessels that surround and supply the nerves are called
vasa nervorum.
The quinolone antibiotics either alter the capillaries permeability, or
induce the deposition of immunological complexes inside them, or
cause a spasm-like narrowing of their ducts. In any case, the result is
the same. Small vessels in muscles, skin, nerves, heart, brain and
other organs are deprived of blood flow (ischemic), or now having
lesions, and they die or do not work properly. Therefore, in this
report we define vasculitis as an inflammation of the vessel walls
with vascular damage or attendant tissue injury.
What nobody knows and requires much more research are the factors
that determine the duration of disease, the type of tissues involved
and their damage, as well as how to target therapies at inflammation
without interfering with healing.
Accumulation of inflammatory cells in the vessel wall is the common
feature of vasculitis, although it is not well understood how tissue
damage occurs. It is widely admitted that there is a three-stage
process:
.. initiation of the injury
.. recruitment of inflammatory cells and tissue damage
.. regulation of the immune response.
Quinolone vasculitis is a systemic vasculitide (so called because of
their multiorgan nature). Inflammation and damage can be transient
or more permanent. The alterations in coagulation and vasomotor
tone result from local damage to the endothelium as well as intrinsic
components of the cytokines that are released through the process.
Drug toxicities are among the causes and processes strongly
associated with vascular injury. Immune complexes with certain
immuno-chemical characteristics activate a complementary cascade
that induces neutrophil mediated damage to the vessel wall. The
presence of granulocytes is usually associated with fibrinoid necrosis
as would be expected on the basis of their release of toxic enzymes
during inflammation. Necrosis in the vessel wall is a large
contributor to scarring and the delayed sequelae present in some
cases of vasculitis like the quinolone-induced vasculitis.
Normally, quinolone vasculitis appears some time after exposure,
and is a link in the chain of adverse events that take place for months
on end. All of the vasculitides are likely secondary to some form of
inflammatory stimulus, usually infectious or toxic, like in our case.
In quinolone vasculitis the underlying real cause either cannot be
identified (no doctor is willing to admit that quinolones are the direct
cause of vascular disorders) or has long since been cleared by the
host, leaving only a chronic or recurrent inflammation centering on
the vasculature.
Overall, vasculitis secondary to a defined infection or toxin is clearly
the most frequently encountered vasculitis and an important etiology
in peripheral nerve vasculitis. Toxins as a cause of vasculitis are
increasingly established. Because quinolone vasculitis is so varied in
its presentation and clinical pace, early identification may be
difficult. In this vasculitis, neuropathies are frequent, occurring in
80%-100% of patients. Mononeuropathy multiplex is the most
distinctive pattern, although nerve alterations of other kinds are very
common too (twitching, throbbing, pins and needles, numbness,
sensory polyneuropathies). See the paragraph devoted to
neuropaties.
There is the issue of diagnosis. The diagnosis of vasculitis is
fundamentally an invasive process. Identification of inflammatory
cells that diminish the delivery of blood to tissue is a critical feature.
Furthermore, the numerous causes that may result in vasculitis can
often be distinguished only at the cellular level. Histological studies
characterizing lesions on the basis of the infiltrating cells may
provide information on both the mechanisms inducing inflammation
and predict the sequelae of the lesions. There is an urgent need to
determine the underlying mechanism for appropriate treatment.
For most floxies the blood studies may be entirely normal. There is
no serological test that confirms or excludes a vasculitis. Quinolone
vasculitis is:
.. seronegative (non-ANCA, negative SSA, SSB, anti-Sm, normal
anticardiolipine, antiphospholipid, soft muscle markers,
halotypes....)
.. drug-induced, non-abating with drug withdrawal, and typically
reaches its acute phase many months after drug discontinuation.
.. not responsive to any known treatment; very long lasting or
permanent.
So, in summary, blood ducts spread in smaller and smaller conducts,
called arterioles and venioles. The real ends of them reach every part
of the body and the red blood cells have to circulate through them
almost in single row. The former ducts bring the oxygen and the
nutrients and the latter ones collect the by-products and CO2 (carbon
dioxide) resulting from cell activity.
There are zones with very little arteriole and veniole supply:
cartilages, tendons, nerves and connective tissue. Due to the
vasculitis caused by quinolones, the inner diameter of the conducts is

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
14/32
narrowed. The result is that the vessels cannot correctly supply the
tissues or take away the waste. The consequences are:
.. lack of blood supply (injury to vasa nervorum) in nerves that
cause intense neuropathy like numbness, tremors, twitching,
tingling, and neuritis.
.. lack of blood supply to cartilage, in addition to the toxic assault,
causes necrotizing, and erosion with osteoarthritis in weightbearing
joints.
.. lack of blood supply in tendons and overuse with daily
movements causes tendinitis.
.. heart arrythmias, palpitations, poundings, that last for years and
in some cases require the implantation of a pacemaker. Many
deaths have been associated with quinolone-induced
cardiopathies.
.. poly-myositis and muscle destruction are frequently seen in
severe reactions.
.. lack of blood supply in the extremely narrow ocular vessels
causes sparkling, zig-zagging, wandering small lights. Floaters
are a result of dying cells due to lack of blood supply. Many
floxies get ischemic areas in the outer margins of the retina.
Optic neuritis is very common.
.. temporary and complete loss of vision, occurring in some cases
from month 5 to month 13th: lack of irrigation of the eyes.
.. lack of blood supply near the skin in the more distant areas of
the body and a tendency to have cool feet and hands
This vasculitis seems to be an autoimmune disease and for short
treatments is responsive to most conventional treatments such as
corticosteroid therapy, immunosuppressive drugs, and the like. In the
case of a severe reaction, long-term treatments with corticoids are
contraindicated (increase very much the likelihood of experiencing a
tendon rupture) and also ineffective.
The search for a non-invasive marker for vasculitis remains
disappointing. Some of the most effective treatments for quinoloneinduced
toxicity are substances with a strong vasodilation activity or
active blood thinners. On the other hand, substances with
vasoconstrictive properties are nearly always detrimental for floxies
and induce relapses, an increase of symptoms and delayed
recoveries.
Remember:
Your problems after the reaction are the tip of the iceberg. The quinolones
have damaged in different degrees all your body systems.
VASCULITIC RASHES
Many severe cases of intoxication by quinolones have a skin rash
present. There is a predilection for the distal ends of the limbs: hands
and feet. The following picture is an example of a vasculitic rash
induced by ciprofloxacin in a young athlete.

These rashes tend to resolve spontaneously, but signal serious
reactions to quinolones.
In all, about 15% with severe or intermediate adverse reactions to
quinolones actually develop a vasculitic rash.
-Picture 1- The points marked as "B" are red points, like pustules but with no
secretion. The point marked as "C" is a purple type of hematoma.
NEUROLOGICAL IMPLICATIONS
The longest lasting damages from quinolones are perhaps the
neurological alterations. Neurotoxicity is a common feature of all
quinolones since such adverse reactions have been described with all
derivatives so far known. Some research suggests that they are due
to the neuromuscular blocking effects of quinolones. Maybe they are
secondary (a consequence) of the vasculitic mechanism.
Neuropathies are a prominent feature of the toxic vasculitides. The
reasons for this frequency are not immediately clear. The rich blood
supply and the capacity of nerves to function reasonably well with
anaerobic (no oxigen) metabolism normally render the nerve
relatively resistant to ischaemia (disruption of blood supply). The
immediate cause of the vasculitic neuropathies is inflammation or
deposition of inmuno complexes that eventually harden, thicken, and
develop scar tissue, decreasing the diameter and impeding blood
flow with occlusion of the vasa nervorum resulting in ischaemia of
the peripheral nerve that end up damaged or dead. This category of
nerve damage, in which isolated nerves in different areas are
damaged, is called mononeuropathy multiplex or multifocal
mononeuropathy.
On top of that, nearly all the floxies have peripheral neuropathy.
Peripheral neuropathy describes damage to the peripheral nervous
system, the vast communications network that transmits information
from the brain and spinal cord (the central nervous system) to every
other part of the body and viceversa. Because every peripheral nerve
has a highly specialized function in a specific part of the body, a
wide array of symptoms can occur when nerves are damaged. Some
people may experience temporary numbness, tingling, and pricking
sensations (paresthesia), sensitivity to touch, or muscle weakness.
Other floxies, particularly in severe reactions, may suffer more
extreme symptoms, including burning pain (especially at night, very
exacerbated by heat), muscle wasting, paralysis, or organ or gland
dysfunction. People may become unable to digest food easily,
maintain safe levels of blood pressure, sweat normally, or experience
normal sexual function.
Some forms of neuropathy involve damage to only one nerve and are
called mononeuropathies that in many cases are difficult to recognize
properly and thus are diagnosed as normal musculoskeletal lesions.
Sometimes two or more isolated nerves in separate areas of the body
are affected-called mononeuritis multiplex. Often though, multiple
nerves affecting all limbs are affected-called polyneuropathy. Toxic
drug-induced neuropathy usually involves nerves on both sides of
the body, although not always symmetrically (many floxies get far
more rigid and painful on one side), and pain is a common symptom.

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
15/32
The neuropaties that we experience are predominantly asymmetrical
and they migrate around certain areas of the body, with a marked
predilection for lower limbs and distal areas (hands, feet).
In short, quinolones damage both central and peripheral nervous
systems. It is very typical to feel pin and needles sensations, as well
as throbbing pains, numbness, trembling, fasciculations (crawling
under the skin), tremors, twitching, and neurological pains migrating
all along the body. In most floxings the associated pain typically
does not respond to simple analgesics, and can become chronic and
may interfere with sleep (more intense in hot areas of the body) and
be present also at rest. Neuropathic pain is difficult to control and
can seriously affect emotional well-being and overall quality of life.
As has been shown earlier, insomnia, nervousness, anxiety,
overreactions to stress, anger and anguish are also very common.
The damage is very extensive and symptoms fit well in many
neurological subdiseases like all kind of peripheral neuropaties:
mononeuritis muliplex, sensorimotor neuropaties, demyelinating
neuropaties, axonal neuropaties, autonomic nerve damage, and many
more specific disorders. Central system neuropaties affect many
organs like heart, eyes, brain and intestines.
PERIPHERAL NEUROPATHY
Peripheral neuropathy, affects a variety of peripheral nerve cells and
fibers, including sensory (temperature, touch, vibration...), motor
(muscles), and autonomic (orthostotic pressure, erection) fibers.
Most quinolone induced peripheral neuropathies affect all fiber types
to some extent. However, a single fiber type may be predominantly
or exclusively affected in some cases producing very particular
neuropaties. In some floxies, peripheral neuropathies involve single
peripheral nerves (single=mono neuropathies), or numerous
individual peripheral nerves, the so-called mononeuritis multiplex
syndrome. In addition, peripheral nerve disorders may involve the
brachial plexus, lumbosacral plexus, or a single root, that is to say,
the low spine, resulting in signs and symptoms in one limb, with
pains that can be excruciating. Most cases of floxing conform to a
polyneuropathy syndrome, which usually implies both sensory and
motor fiber involvement in a relatively symmetric fashion and
typically with a distal-to-proximal gradient of involvement (more
intense the more distant from the trunk). These conditions are termed
sensorimotor polyneuropathies, and they represent the most common
form of peripheral neuropathy.
Quinolones can induce pathologic reactions in the nerves: wallerian
degeneration, axonal degeneration, and segmental demyelination. In
wallerian degeneration, the axon degenerates distal to a focal lesion
that interrupts the continuity of the axon. This reaction often occurs
in focal mononeuropathies that result from nerve infarction as a
result of a schemic vasculitic process. The toxicity plus the ischemia
interfere with nerve metabolism. They affect the longest neurons
first, since long neurons have greater metabolic demands than short
ones. Symptoms therefore may begin in the feet, then progress up
the legs and then affect the hands. It is a typical pattern.
Axonal (rod) degeneration, starts at the most distal (distant from the
trunk) extent of the axon. Axonal degenerative polyneuropathies are
usually symmetric, and are not common in floxings. However
floxies show predominantly signs of segmental demyelination, that
refers to focal degeneration of the myelin sheath with sparing of the
axon. This reaction can be seen in focal mononeuropathies but also
in generalized sensorimotor or predominantly motor neuropathies.
Toxic segmental demyelinating polyneuropathies might be the result
of the inmunological reaction.
In those peripheral nerve disorders that are characterized by either
wallerian degeneration or axonal degeneration, prognosis (likely
outcome) is less favourable due to the fact that the axon must
regenerate and reinnervate muscle, the sensory organ, blood vessels,
and other structures before clinical recovery is noted. Recovery may
be more rapid with segmental demyelination because remyelination
is accomplished more quickly, in turn reestablishing normal
conductivity of the axon and return of function.
It is easy for the floxie to feel and describe the symptoms of his/her
peripheral neuropathy.
Sensory symptoms: Sensory symptoms include sensory loss, a sense
of numbness, tingling, prickling, and pins-and-needles sensations,
pain, thermal sensation, vibratory sense and intolerance to light
touch. Damage to large sensory fibers lessens the ability to feel
vibrations and touch, resulting in a general sense of numbness,
especially in the hands and feet. People may feel as if they are
wearing gloves and stockings, or having the foot in a cast. In most
generalized polyneuropathies, these symptoms begin in the most
distal (far from the trunk) extent of the longest sensory fibers, like
the toes and feet and then crawl their way up to the knees point in
which the disorders also starts at the fingertips spreading the process
to the upper extremities. In addition to sensory loss, patients
frequently complain of paresthesias and dysesthesias, often
characterized by a sense of numbness. Pain is a serious symptom for
many floxies. It may be described as a dull aching sensation, an
intense burning sensation or, occasionally, as intermittent lancinating
pulses of pain (called throbbing in this report).
Motor-muscle: Muscle weakness is the most common symptom of
motor nerve damage. Other symptoms may include painful cramps
and fasciculations (uncontrolled muscle twitching visible under the
skin), muscle loss, bone degeneration, and changes in the skin, hair,
and nails (these more general degenerative changes also can result
from sensory or autonomic nerve fiber loss). Impairment of motor
function typically begins with weakness in the toes, and as the
polyneuropathy progresses, ascends up the distal lower extremities to
the level of the knees, at which time motor involvement in the hands
may be observed.
In the toxic segmental demyelinating polyneuropathies, proximal
muscle (quads) weakness resulting from root
(polyradiculoneuropathy) involvement may be observed. Axonal
degenerative polyneuropathies tend to produce weakness along with
muscle atrophy, but atrophy is much less conspicuous in segmental
demyelinating polyneuropathies because in these disorders the axon
remains in continuity with the muscle, preventing denervation
atrophy. Therefore, your doctor can measure your thigs perimeter
and tell you that finds both the same size, eventhough you feel your
painful one nearly useless, soft, iddle and deprived of strenght.
The most common symptom (but not unniversal) in severe floxing
polyneuropathy is weakness in dorsiflexion of the great toe. That
disability is somehow a measure of the initial severity of the
polyneuropathy.
Autonomic nerves: Some floxies report symptoms that evidence that
autonomic fibers are also affected. Symptoms of autonomic nerve
damage are diverse and depend upon which organs or glands are
affected. Autonomic nerve dysfunction can become life threatening
when the heart begins beating irregularly (extremely common in
floxies) or there is difficulty with breathing. Other common
symptoms of autonomic nerve damage include an inability to sweat
normally (floxies notice reduced or absent sweating in the legs and

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
16/32
hands, and at the same time excessive sweating confined to the head
and neck region), a partial loss of bladder control and an inability to
control muscles that expand or contract blood vessels to maintain
safe blood pressure levels. A loss of control over blood pressure can
cause dizziness, lightheadedness, or even fainting when a person
moves suddenly from a seated to a standing position (orthostatic
hypotension).
In severe floxings other autonomic symptoms include dryness of the
eyes and mouth (another marker of the severity of the floxing) and
gastrointestinal dysmotility (nerves controlling intestinal muscle
contractions often malfunction), often manifested by alternating
constipation and diarrhea or by early satiety. Many people also have
problems eating or swallowing if certain autonomic nerves are
affected. In intermediate and severe floxings in men, partial erectile
dysfunction or incontinence is one of the first autonomic symptoms.
Diagnosis. Such a vast array of presentations of peripheral
neuropathy in floxies makes precise diagnosis a challenging task and
is the reason that physicians get to different conclusions depending
on the predominance of the axon/myelin, phocal/diffuse,
symmetric/asymmetric, sensory/motor/autonomic involvement, and
adding the difficulty posed by the fact that floxies develop all of
them in different grades.
Doctors may order a set of tests to evaluate your disorder: nerve
conduction studies, needle electrode examination, brain and spine
MRI, lumbar puncture for cerebrospinal fluid analysis. Blood and
urine works can include glucose tolerance test, vitamin B12, serum
protein, anti-GM1 antibodies and anti-myelin antibodies, plus
investigations of markers of various connective disorders associated
with vasculitis. The ultimate analysis is a nerve biopsy, that when
performed with the most advanced technics by well trained
physicians can assist in the complete characterization of the lesions.
It is an invasive procedure and few floxies have undertaken it
because is mainly ordered only in severe reactions and when a
diagnosis of vasculitis or inmune reaction of other sort is being
considered. Less common are precision sensory testings, and studies
of sudomotor function, and autonomic responses to provocative
physical maneuvers.
In many cases the electrical conductivity tests render normal results,
as well as MRIs of the brain and spine, and spinal taps. But it is also
very typical that well conducted studies discover alterations in the
sensory and motor status of the nerves in many parts of the body.
Muscles also show decreased responses in electromyographic
(EMG) studies.
Other very common findings are decreased or altered signals in the
nerves that control the hands, especially the ulnar nerve. You will
know that your ulnar nerves are affected if your small and ring
fingers become numb, normally if you exert pressure around your
elbow or when bending your elbows sleeping at night. Some doctors
will tend to diagnose you as having ulnar or carpal tunnel syndrome,
but you are really suffering toxic ulnar neuritis.
Other nerves very commonly implicated are the nerves of the legs.
Pains occur predominantly in the hamstrings, lateral or medial knees,
outer gluteus, calves, quads, groin, and several areas of the ankle,
plus the toes. Many times pains mimic strains, tendinitis, muscular
fiber disruptions, sprains, but they are toxic neuritis.
Remember:
In severe reactions neurological pains can last for years and impair your
life’s quality.
In general, we have multiple peripheral nerve lesions. They can
occur sequentially and in a random fashion (now the upper left leg,
then the right ankle, ..). As said before, the earliest findings are loss
of vibratory sensation in the toes, atrophy of intrinsic foot muscles,
and reduced or absent ankle jerks. In severe reactions there are signs
of lower motor neuron lesions: weakness, more generalized atrophy
and fasciculations.
Double or triple mononeuritis dominates in intermediate reactions.
For instance, the right leg (hamstring and ankle-Achilles) plus heart
arrhythmias and perhaps an elbow epicondylitis. Multiple neuritis is
more typical of severe reactions. For instance, this includes the right
leg, plus heart disorders, plus elbow, shoulder, hips, wrists, and
above all- optic neuritis.
Optic neuritis reflects a lesion of the optic nerve and is a secondary
effect of the damage caused by the quinolones to the small blood
vessel complexes of the eye (in fact is an ischemic optic
neuropathy). The optic nerve dysfunction usually manifests with
blank spots, difficulties in focusing, and in severe cases transient
complete losses of vision with a solid white vision in one or both
eyes. These blindness episodes have been reported with
ciprofloxacin and last for some minutes, are very scaring, appear
suddenly, so they are also dangerous depending on the activity upon
which the floxie is on. These blindness events can happen
periodically up to 18 months after the treatment with ciprofloxacin
and at any time for the following years if the floxie gets a high reexposure
to quinolones through poultry ingestion for instance.
If the intoxication of the quinolones has been intermediate, these
neurological symptoms tend to dissapear in two years time on
average. If the intoxication has been severe, the neurological
disorders linger on for many years without abating, although for the
4th or 5th year mark the floxie can experience an improvement.
CONSTANT PAIN ALL OVER. MYALGIAS
Besides the neurological pains, in severe reactions constant, intense
and spread all over pains are very common. Basically they are drug
induced myopathies, again probably secondary to the vasculitic
reaction. The major symptoms in drug induced myopathies are
proximal muscle weakness (quads, hamstrings, shoulder, biceps,
triceps), increased muscle enzyme levels, electromyographic
changes and histological lesions. Quinolones induce painful
myopathies associated with neuropaties, that could be called painful
neuromyopathies. It is typical of these neuromyopaties a free period
between the beginning of the treatment and the appearance of
symptoms, and incomplete resolution after withdrawal of the
treatment.
OTHER DISORDERS YOU MIGHT EXPERIENCE
Quinolones are very toxic drugs for the liver, pancreas and kidneys.
Half of the quinolones marketed since their creation have been
withdrawn from the market because of their potentially fatal toxic
profile. Some had a marked inclination to destroy the liver
(trovafloxacin), others the heart, and all are very toxic to vital organs
as a class effect. It is not uncommon to get abnormal results in serum
tests for many months after discontinuation of the drug.
On top of the general problems that you may have due to the toxicity
of the quinolones, many people have additional problems, due to

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
17/32
alterations of functions or systems that were working well but in
delicate equilibrium before taking the quinolones. For instance, if
without knowing it you suffered a little osteoarthritis because of
overuse during your endurance sports, a short leg, asymmetrical
muscle mass, lack of flexibility or the like, all of them will become
very noticeable when your floxed body cannot compensate for any
minor flaw.
When you suffer strong quinolone-induced neuropathies of the
extremities, you will experience atrophy (wasting) of the main
muscles. Sometimes it is very difficult to detect unless tested by a
professional. Muscles most frequently subject to wasting are the
tibialis anterior, soleus, gastrocnemius, vastus medialis, the other
quadriceps muscles, shoulder and forearm muscles.
Atrophy of the muscles that control a joint make this joint more
prone to injury, normally from repetitive loads. So the vicious cycle
starts: the neurological lesions waste the muscles, so joints are
overloaded, or eccentrically or abnormally loaded, and they degrade,
creating another layer of pains and disability that blends with the
previous one and that contribute to a never ending “snowball effect”
injury.
So, it is important that as soon as you feel well enough that you
begin a stretching and strength training program for your most
affected joints.
The neuropaties caused by fluoroquinolones also affect the nerves
that control the chest muscles, so the floxie tends to breath
abnormally, with very shallow chest movements. As a result, not
enough oxygen is introduced in the system, and some metabolic
processes get even more impaired. Insomnia is greatly worsened by
shallow breathing.
THE PSYCOLOGICAL ASPECT IN SEVERE
REACTIONS
You were a young active person, lead a healthy life, and ate healthy.
You had a good job and were a brilliant professional. Your family is
lovely. You just had a minor health problem like a sinus infection, a
sore throat, a urinary tract infection or a suspected or actual
prostatitis. You trusted your medical system and you were prescribed
a quinolone antibiotic. Finally, you have had a severe reaction.
Now you cannot play any sport, not even playful wrestling with your
children. You have cognition problems that disrupt or stress your
career. You can hardly sleep. Your vision is constantly bothering
you reminding you the whole day long that you are ill. You feel
constant intense and weird pains, you cannot sit in any comfortable
position, you have problems getting in and out of the car, and you
resemble an 80- year old man. You have to watch what you eat
carefully, so you are barely able to attend social events anymore. For
months on end your symptoms get worse by the day.
Some nights you cry in solitude. You have little understanding
and/or compassion from your loved ones because you still look
normal on the outside. It is 3 years since you got hit and your
youngest child does not know how you were like before the floxing
because he was too young, he only knows you as a permanently ill
father that cannot even eat normally. Perhaps your co-workers think
that you are exaggerating or pretending that you are ill. Your doctors
are not willing to listen to you correlating your problems and
symptoms to a fluoroquinolone antibiotic. After a year or so, your
symptoms have gotten worsen, but surprisingly all of your
acquaintances, friends and relatives give up sympathizing with your
situation because it is lasting so long, so you start to feel more alone.
Many suggest, or tell you boldly, that your problems are all in your
mind. Most tests are negative so you remain undiagnosed. All severe
cases reveal abnormalities in neurological studies but they are
attributed to physical compressions and they offer you a surgical
release that you know won’t fix anything. Nothing seems to help
with your recovery. Nobody seems to have any knowledge about
your disorders. You spend enormous sums of money and time in
doctors and paliative therapies.Your daily life is a constant struggle
against your illness, and you cannot release yourself from your daily
obligations because nobody acknowledges your chemically altered
state, so you become stretched to the limit.
After the first stage, in which you just fight for mere physiological
and psychological survival, one day you find yourself staring at
people just getting out of the car, sitting in awkward positions,
walking up stairs, walking normally, eating a normal food in a good
restaurant, planning to trek, bike, travel or play, and dream of a day
in which you will also do it as effortless and so unaware of doing so
as you did before the floxing.
Note:
Try to seek help from loved ones and caring doctors. You will need it.
You are going to need some help, either from a professional, your
family, from friends or from support groups. But it is very difficult
for a non-floxed person, even a loving and caring one, to truly grasp
the magnitude of your chronic suffering from a quinolone antibiotic.
This is not a matter of weeks or months, but of many years. After 2
or 3 years you cannot remmember any longer how was like to feel
allright. You become increasingly weary and long for a normal life.
You are scared about the permanent injuries you seem to be facing,
and above all you do not know what lies ahead in terms of
limitations and deterioration. Your mental drive sometimes falters
and you are overwhelmed by the floxing in every way. Depression
will linger. Suicidal thoughts are not uncommon, but in most cases,
are short lived or insufficiently based, although repetitive. Some
floxies have taken their lives.
Be prepared for very distressing and dishearting states of mind and
body and be determined to keep moving forward. Stay positive as far
as possible. Time is your only real friend in this unequal and unfair
fight. Mild and INTERMEDIATE floxings usually have a happy
end. After a severe floxing it is unlikely that you will recover
entirely your former self. After realising it you will have to admit it
and then reschedule your life for it.
MIXED CONDITIONS
This report does not deal with a floxing in context with other
previously existing health conditions. Floxing is a very debilitating
illness in and of itself, but its complications can multiply if before
the drug intoxication there were other pre-existing disorders like
lupus, lyme rheumatoid arthritis, multiple sclerosis or even
osteoarthritis.
DIFFERENTIAL DIAGNOSIS
There are an array of illnesses that share common ground with the
floxing syndrome (QTS). In all the cases we should consider the
drug- induced version of each disorder:

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
18/32
.. Fibromyalgia
.. Multiple sclerosis
.. Rheumatic diseases (rheumatoid arthritis, reactive arthritis)
.. Poly-myositis, inclusion body myositis
.. Steven’s-Johnson syndrome
.. Serum sickness
.. Sjogren’s phenomena and syndrome
.. Small vessel vasculitis
.. Systemic lupus erythematosus
.. Poly-neuropathy, mononeuritis multiplex
.. Rhabdomyolysis
.. Toxic syndromes and neuromuscular disorders
In some cases, the quinolones do release true autoimmune responses,
so they trigger or induce real rheumatic diseases, and all the illnesses
listed above, as well as many others (see references at the end),
some of them leading quickly to a fatal outcome.
Therefore, your doctor has to conduct a discarding process oriented
to discern and obtain a clear diagnosis. In the best cases, you will be
diagnosed as suffering from one or more of the following conditions:
.. Sensorimotor, autonomic, sensory peripheral neuropathy
.. Mononeuritis multiplex, focal polyneuropathy,
.. Peripheral neuropathy, systemic neuropathy
.. Vasculitic neuropathy
.. Myositis, polymyositis
.. Myasthenic syndrome
.. Vasculitis, small vessel, reactive, toxic
.. Vasculitic myositis
.. Cardomiopathy
.. Optic nerve myopathy, schemic neuropathy
.. Connective tissue disorder
.. Tendinitis, tenosynovitis, enthesitis
.. Osteoarthritis, fibromyalgia
In extreme cases, autoinmune disorders released by the quinolones
like lupus, sclerosis, arthritis, sjögren’s, raynaud’s, and many others..
Therefore, your doctor has to conduct a diagnostic process directed
at discerning and obtaining a clear diagnosis.
AVOID ANY PHYSICAL TRAUMA
It has been elucidated above how normal strain on a floxie can have
more serious consequences than on a normal person. In severe
reactions, small blows or edemas can cause a flare up of minor
neurological problems all over the body in less than two hours; for
example, twitching, lack of jaw coordination, tremors, as well as
local alterations much more intense than usual.
Severe impacts or traumas directed against a limb (a quad or a calf
for instance) can be devastating for a floxie. The inflammatory
process in the area will affect the main nerves and trigger a neuritis
that can take several years to resolve. So, an injury that in normal
conditions would request 1 to 3 months to heal can be a long-term
threat, or become a chronically impairing condition for a floxie. This
provides another clue for investigators because it is clear that there is
a link between the processes of inflammation and the exacerbation of
the floxing conditions. After the traumatic event, there is a release of
mediators in the bloodstream that induce alterations of the vessels all
over the body and also promote the arrival of immuno-complexes to
the site of the injury. Some of these compounds and mechanisms
could be the same as the ones that cause the damage induced by the
chemical toxicity of quinolones.
For the examples cited, in the case of a blow on a quad, the neuritis
can affect the whole upper leg, from buttock to knee, providing
strong, stabbing neurological pains to the sufferer. A traumatic event
in the calf, can initiate a neurological response in the outer (lateral)
knee, and in the achilles' tendon.
AVOID RE-EXPOSURE TO QUINOLONES
Even if you have not been exposed to quinolones before do not take
any quinolone antibiotic unless strictly necessary.Do not ignore the
possibility of suffering from a floxing syndrome if you have
experienced the symptoms listed above and have taken quinolones in
the past.
In any case, do not take any quinolone antibiotic unless it is
absolutely necessary. Do not allow yourself to be prescribed
anymore quinolone antibiotics. The re-exposure will bring you
devastating and possibly permanent damage that could become a
life-long condition.
Do not accept your doctor’s prescription for a quinolone antibiotic
without having checked for other alternatives and/or safer, less toxic
drugs; and never take a quinolone on the grounds that “according to
his experience” quinolones are effective, well tolerated, with
minimal side effects as antibiotics. His experience is reduced to
prescribing quinolones in the "fire and forget" manner (handing them
out like candy), and not caring for the patient’s adverse effects
caused over time.
Remember:
After any kind of reaction if you ever take another quinolone the side
effects can be tragic and unmanageable.
THE MAIN QUESTIONS REMAIN UNANSWERED
Apparently, there are no answers for the main questions that afflict
people suffering from the floxing syndrome.
.. The scientific questions in desperate need of answers are:
.. Which are the mechanisms of the damage?
.. Does the drug remain in the body (tissue bound) after the
treatment cessation?
.. Why do the most severe symptoms develop months after the
treatment?
.. Is there a condition that makes some people more prone to
being damaged?
.. How deep is the neurological damage?
.. Why some foods and substances trigger another amplified
reaction?
.. What are the permanent internal lesions we are facing?
.. What type of recovery period is to be expected?
.. What can be done to limit the extent of the damage caused by
these toxic chemical antibiotics?
.. What can be done to help or expedite the recovery?
Obviously, there is insufficient scientific research on the subject of
quinolone toxicity. And to date there is no known cure. It is difficult
to understand why with so much clinical data available from us as
victims and the availability of willing volunteers for studies, no
scientific research is done on a great scale. The negative influence
and pressure of the drug manufacturers is the only explanation as to

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
19/32
the reason for eluding and avoiding such desperately needed
research.
From the social point of view, the critical questions about the subject
are:
.. Why nobody undertakes a follow up (OVER A MINIMUM
PERIOD OF THREE YEARS) study of large populations of
people that have taken fluoroquinolones, (especially long-term
treatments) like the U.S. postal workers?
.. Why the public health administrations do not begin a true, real,
and accurate study, and not merely a manipulated or washed
over study, about the safety of the quinolone class of antibiotics,
taking into account that half of the quinolone family of
antibiotics have been withdrawn from the market over the years
due to severe toxicity?
.. Why quinolone antibiotics are not strictly forbidden in the
raising and production of cattle, poultry and fish for human
consumption, because substantial amounts of the antibiotic
remain in the food, irrespective of the time elapsed from
administration to slaughter, and pass on to unsuspecting people?
Many thousands of people are diagnosed every year as having
fibromyalgia, osteoarthritis, immune disorders and neurological
problems, when in fact they are just poisoned from a quinolone,
either by direct ingestion through a drug prescription or through the
food supply (poultry, beef, fish, dairy).
WHY DOES THE MEDICAL CLASS IGNORE THE
TOXICITY OF QUINOLONES
Being floxed is a very hard, life-altering experience, and sometimes
a life experience of misery and accelerated physical and mental
decay. You have to be prepared to add your doctor's ignorance to
your despair. The average doctor, irrespective of his/her
specialization, is fed technically on propaganda from the drug
manufacturers. Manufacturers generously sponsor medical
magazines, many medical reports, symposiums, conferences, and
travel. Their advertising and information highlights the alleged
benefits of quinolone antibiotics, hiding the true toxic profile.
Prescribing doctors know virtually nothing about quinolones and
their use, apart from the biased information provided to them by the
laboratories and drug companies. The main and nearly only technical
information the doctors have about these drugs comes from the
advertisements in the medical magazines and visits from the drug
representatives of the manufacturers. So they all think that
quinolones are very safe drugs.
More than 90% of all the prescriptions of quinolones could be
avoided, using other safer, less toxic antibiotics. It is very normal
and standard for urologists to prescribe a long-term course of
fluoroquinolones for a suspected case of prostatitis without obtaining
a culture test or more definite diagnostic.
The arrogant ignorance of the medical class puts them in a situation
prone to block any input and knowledge from their patients. The vast
majority of the doctors will not listen to their patients complaining of
the first signs or pains associated to the drug reaction. If your doctor
tells you "it cannot be the drug" you are dealing with one of these
doctors. They are firmly convinced that they behave professionally
but in fact they are just frivolously superficial.
Your doctor is likely to dismiss any of your complaints if you
suggest a link to the antibiotic. He will probably tell you that it is
impossible, that you should never read about medical issues on the
internet, and that this is the first time he heard of something like this.
If he despises your arguments, saying that you are the first person
that he has met with these complaints, then he is unable to learn and
cannot get beyond his limited understanding and awareness. You
definitely need another doctor at this point.
A typical doctor is not willing to accept information from his/her
patients. He does not care for them and he will not make a follow up
of their progress. There is not a single urologist or doctor that asks
his patients for adverse effects one or two years after having
administered them 6 weeks of ciprofloxacin (2x500mg/day), when
all of them would relate the whole myriad of symptoms described
previously in this report. In other words, he cannot discover delayed
symptoms. There are reputed doctors that treat their fibromyalgia
patients with quinolones; that is the same aberration as using the acid
from your car's battery as eye drops for a pollen allergy. We have a
strong suspicion that many fibromyalgias are caused by the ingestion
of quinolones and other toxins through the diet. If you are in one of
these situations you have to choose whether to follow your doctor's
advice, or think twice and look for a second, and even third opinion.
In the end, the only thing at stake is your life.
But not all doctors are equally ignorant. In the primary care system
we have found quite some of them that never, under any condition
prescribe a flouroquinolone because they have concluded from study
and observation that they are extremely toxic antibiotics that should
be reserved for life or death cases.
In the scientific field there are many researchers that share the same
opinion. Some medical investigations have already pointed out the
shocking toxic profile of the quinolones. According to some articles
that you can consult in the reference list, there has been an important
time-lag between the first reports of fluoroquinolone-related
tendinopathies and the official recognition of this toxic phenomenon.
Those doctors argue that this delay, along with the widespread use of
fluoroquinolones, makes it difficult to return to more reasonable
prescribing guidelines for these –for them- very useful and effective
anti-microbials. The reasons why potentially serious adverse effects
of fluoroquinolones were not anticipated before their
commercialisation may be related to the lack of adequate in vitro and
in vivo models, and the unexpectedness of the events. Increasingly -
their argument follows- fluoroquinolones are being prescribed for
benign infections of the urinary or bronchopulmonary tracts.
Sometimes, they are even used for antimicrobial prophylaxis before
surgical or endoscopic procedures.
Those investigators believe that for any prescription, the risk/benefit
ratio of the fluoroquinolones should be carefully considered, since
better tolerated, less expensive drugs can usually be prescribed.
Clear information dedicated both to physicians and patients
regarding the cautions for use and possible adverse effects of
fluoroquinolones would help reduce the risk and severity of adverse
reactions. They state that this is especially important for
phototoxicity, tendinopathy and cardiovascular adverse effects. We
would also add the rest of extremely serious reactions related along
this report.
And they finnally identify the key error that many victims are
denouncing since the ninetees: given the absence of an adequate
model and the poor predictivity of animal manifestations in lesions
in humans, careful monitoring of patients during phase II and III
trials and, more importantly, long term pharmacovigilance during the

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
20/32
postmarketing period, are an absolute need. But despite patients and
researchers claim, it is not being done. The manufacturers of these
drugs would not allow it and the FDA acquiesce.
Note:
Comment with your doctor your concerns. Ask him to get informed
because he is the person that can help you best.
If you want your doctor to cooperate you have to first convince him
about the real toxic nature of the quinolone antibiotics. You will
have to bring him some good papers like the ones published by
Doctors Cohen and Casparian. You may get some help if he takes
interest in your story.
THE REAL COST OF A CIPRO PILL
For society as a whole, the real cost of a 500 mg pill of a quinolone,
taking into account the damage inflicted on so many, measured by
the working hours lost, diagnostic procedures, the expenses in
palliative treatments and medical bills, is not less than 800 dollars
per pill, for at least 20% of those that take quinolones.
In other words, every 500 mg pill of cipro or levaquin taken in
Europe and the United States has a real cost of at least 160 dollars on
average. The hi-tech drug system has released a toxine that circulates
disguised and freely through the primary care offices, hospitals and
specialized doctors, that saves momentarily some inconveniences to
the patients but that requires a huge economical effort to fix its trail
of damage, and also spreads a lot of human suffering.
I NEED TO TAKE AN ANTIBIOTIC. WHAT SHOULD
I TAKE?
You are scared to death. But there is no other choice because you
have a proven infection and the mild all-natural antibiotics will not
clear it. This time you search frantically for a class with no adverse
effects, but you do not find any. An allergic reaction to any food or
drug is always possible but we do not discuss it here.
When you are floxed, any virus or bacteria that you catch will
release a relapse. Your symptoms will cause you to deteriorate
rapidly and in a couple of days you will find yourself months behind
in your recovery. Perhaps the release of white cells into the
bloodstream or other mediators alter the status of the micro-vessels,
either by clogging them or by some other mechanism. So it is
important to get as few infections as possible.
You have to discuss it together with your doctor and choose a class
of antibiotic that is both effective against the bacteria and has as safe
a profile as possible. Your search should be directed to avoid
antibiotics with a high record of neurological or vasculitic adverse
reactions. Medical literature has well stablished that: beta-lactams
and the quinolones are the drugs most commonly associated with
seizures and encephalopathy; the aminoglycosides, tetracyclines,
clindamycin, erythromycin, polymyxins, and possibly ampicillin
have the potential to aggravate neuromuscular disease; ethambutol,
isoniazid, and chloramphenicol are toxic to the optic nerve; bismuth
can cause a myoclonic encephalopathy, macrolids are linked
especially with vasculitic events and also quinolone-wise with
prolongation of the QT interval of the heart. Beta lactams have also
been implicated with serum-like sickness, a condition very similar to
floxing in some aspects. Sulfonamides can also release lupus,
another illness that shares a lot of ground with floxing syndrome.
Penicillin is much studied and therefore many adverse effects have
been found but it is still a choice. Some antibiotics cause total
hearing loss and other severe lesions.
Never use a quinolone eye drop if other antibiotic can do the job.
The quinolone will kill the bacteria for certain but at the same time
will damage your eyes irreversibly.
There is not much left to choose from, so in the end you have to take
a risk. It is unlikely that a new antibiotic of a different class will give
you so much damage as the damage you are sustaining from the
quinolones. Hopefully, through careful selection or by means of a
couple of attempts you will find one that works well for you with no
more adverse consequences.
ADEQUATE EATING AND HABITS
Mild and intermediate reactions do not request a specific recovery
program. They can more or less heal on their own. For severe
reactions healthy conduct and healthy foods are all part of a recovery
plan. Each of us reacts differently, and there is a lot of controversy
about this issue, but on average, there is a very common core of
reactions that allows us to establish some recommendations. Stick to
your already healthy diet. If you develop intolerances or bad
reactions to some foods (very typical), avoid them during the years
to come.
Obviously, it is strongly advised to avoid any quinolone or
fluoroquinolone antibiotic; and to also avoid any meat, fish, dairy,
eggs or animal product that has been treated with quinolones. Some
contain concentrations of quinolones that are up to 50 times higher
than concentrations in human tissues during a standard treatment,
and can release relapses that range from mild to very severe. Do not
believe food producers or health protection agencies if they tell you
that is safe to consume meat or poultry that has been kept off
antibiotics for 3 days before slaughter. It is not safe, the quinolones
are not fully excreted, and enough of the drug remains in the tissues
to bring you a very severe relapse.
Sugar has an adverse influence increasing insomnia, restlessness and
neurological pains. Alcohol is also vasoconstrictive and a toxic for
the neurological system, so it is better to avoid it. Caffeine is not
metabolized by the floxed body so it can increase your insomnia
problems. Apparently tomato increases neurological pains, perhaps
because of its acidity.
Do not allow your cholesterol to drop too low. Maintain it a little
higher than your normal level, assuming that your normal level is ok,
obviously. Take regular supplements of omega-3 fatty acids from a
reliable manufacturer. It is also beneficial to take some red peppers,
garlic and onion, but do not mix large amounts of these with other
supplements that they could interact negatively with or amplify their
actions.
The main points to address are the inmune reaction and the vascular
lesions. Many flare ups are clearly linked by floxies with the
ingestion of quinoloned food, but others that seem to come out of the
blue are in fact due to new releases of inmune compounds and
constrictive actions. You can act wisely if you assess every activity,
food and supplement from their inmunological activity and blood
thinning and vasodilation properties. You can rate them as IgG
producer, thinner, thicker, vasodilator, vasoconstrictor or neutral.
Obviously blood thinners and vasodilators will benefit you, and IgG
producers, thickers and vasoconstrictors make you prone to relapse.

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
21/32
In all cases we are talking about habits, foods and supplements.
Remember:
Massive residues of quinolones are found in poultry, fish and cattle
industrially raised, enough to bring you a strong relapse.
In general, avoid cold in the extremities. It slows recovery. Use a
sauna occasionally, if you can. Avoid stressful situations and
especially those that release strong hate and anger emotions because
they naturally raise cortisol levels and other hormones that target the
nerves and a number of vasoactive autocoids and hormones that
exert dilatory and constrictive effects resulting in negative
consequences for the floxie.
DRUGS THAT HELP
We do not promote taking any drug and if you need or plan to do so,
then ask your doctor. Many people take drugs for neuropathic pains
(Neurontin and others), normally with good or no results. Other
people get benefits from heparin for its profound effects on capillary
permeability and anticoagulant properties, as it increases the traffic
of substrates and waste products across the interstitial compartment
between cells and vessels.
Every drug that uses the P450 liver cytochrome pathway for its
metabolism will probably have a detrimental or excessive effect on
the floxie because that mechanism is damaged by the quinolones and
the concentrations of the drug can be much higher than expected.
It is better to avoid any medication that causes vasoconstriction, like
anti-inflammatories (NSAIDS). If taken during months 0 to 5 they
exacerbate the neurological symptoms and joint pains. There seems
to be no problems with them from then on except in the event of
severe floxings.
Corticoids may help in the first stages. They can modulate, reduce or
suppress the autoimmune reaction, so they could be a treatment of
choice but not for severe cases. There are reports indicating complete
and prompt healing of quinolone reactions after some days of
administration of cortisone. Many people have stated that their
symptoms returned once the corticoid treatment was stopped. Longterm
consumption of corticoids is associated with greater risks of
rupturing major tendons for floxies..
After the acute phases, when a severe reaction has become chronic, it
is not advised any treatment for your quinolone pains based on the
use of corticoids. They will enlarge the problem, and will make
tendons much proner to rupture. Stay away of antiinflammatories as
much as possible. In severe reactions antiinflammatories always
exacerbate pains in the worst affected areas, while in mild reactions
that negative effect migh not be felt and therefore provide some
relief for the pain.
Many of the commonly prescribed drugs for treating the floxing
syndrome interact negatively with many natural supplements, so you
should pay special attention to this fact and not mix drugs and
supplements unless you are absolutely certain of their compatibility.
RECOMMENDED SUPPLEMENTS
For mild and intermediate reactions it is wiser not to take anything.
In severe reactions the miserable quality of life for months on end
exerts a lot of pressure on the search for a drug or supplement that
would help in healing or to promote and expedite recovery. Out of
despair floxies tend to think that if an approved and hi-tec drug has
brought them such a tragedy why shouldn’t they look for an antidote.
Unfortunately there is not such a miracle substance; but there are
some products that may help to overcome pain, chronic insomnia
and disability. Supplements can be harmful too, if taken in excessive
doses, if they interact with other substances or drugs you are
currently taking, or simply if you are intolerant to them. You will
have to avoid temptations of overdosing with vitamins and
supplements, trying desperately to speed up your recovery.
However, therapeutical and medically controlled doses of vitamins
and supplements plus time is the only treatment advisable to date.
Adjusting the dosages is a real challenge. Sometimes we stick to a
very low dose and end up believing that the supplement is useless
when in reality can be very helpful in higher doses. Other times we
tend to take really high doses without any need for them. Remember
always that twice the dose of a good thing does not double its effect
and in fact can turn it in to a venom. Normally supplements should
be taken a few at a time, for some weeks and then shifting to other
combinations.
Very often the floxie that has not been sufficiently informed starts
taking a lot of supplements together not being aware of the dangers
of interactions or increased action of some combinations. Take also
into account that many floxies are sure that the best choice is to stay
away of any supplement. Unfortunately there are contradictory
experiences. For everything you plan to take, you should consult
your doctor.
Central nervous system (insomnia, restlessness) and vision problems
tend to benefit from foods and supplements that have blood thinning
or vasodilatory properties. For the neurological problems, long term
treatments with vitamins B1, B12, benfothiamine and vit B
coenzymes help. There is some scientifical evidence that citidine
plus uridine (sodium salts CMP, UTP, UDP and UMP) may help to
restore the myelin sheath. Some preparations of vitamins B can be
also neurotoxic, so it is specially important not to surpass the daily
recommended doses.
Berry (cranberry, bilberry) extract seems to be especially effective in
later stages of the floxing because of its modulatory effect on the
smooth muscle of the blood vessels, and also its blood thinning and
vasodilation capabilities. High doses can induce internal bleeding
because of alterations in the thinnest walls of the vasa vasorum.
Other blood thinners have shown some promising therapeutic effects
for floxies like ginkgo biloba, for instance. It would be interesting to
find out whether a combination of one of these thinners plus
magnesium taken in the early stages of a severe floxing (months 1 to
6 or so) could halt the evolution of the lesions.
For vision problems, it is recommended some combination of
vitamins A and E, plus zinc, manganese, copper and lutein. Bilberry
has in its own also a very noticeable effect in making floaters less
noticeable and suppress ziggies and flashies.
It is well assumed that magnesium can help because of its
vasodilator effect and its soothing capabilities on the nervous system.
It is important not to become magnesium deficient. There are many
medical articles that show that a deficiency in magnesium levels
aggravates the floxing symptoms and lesions. Some floxies have low
serum magnesium levels. A combination of calcium and magnesium
seems to work more efficiently. Some vitamins are especially
helpful, like vitamins C and E, but never in mega-dose preparations
that are sold over the counter. As an example, vitamin E shouldn’t be

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
22/32
taken along with any blood thinner (bilberry, gingko, garlic) because
of the risk of hemorrhage.
To break some acute reactions special supplementations with simple
amioacids can help. Aminoacids like arginine, glutamine and
carnitine are usually effective in limiting the pains or progression of
the symptoms. Apparently L-carnitine can help in the restoration of
nerve endings in the long run. Alpha lipoic acid is used for the
neurological pains with mixed results and its role seems more related
to its antioxidant activity with little adverse effects.
In many cases, quinolones create and additional problem killing the
friendly bacteria of the gut, and allowing fungi to proliferate
(candidiasis) as well as releasing a malabsortion syndrome or leaky
gut (damage of the lining of the intestine, impeding the normal
breaking down and filtering of food elements). This syndrome poses
a lot of problems in terms of lack of absorption of nutrients,
toxicities and reactions to foods, so some multiminerals preparations
will be helpful to replenish the normal levels of minerals. In order to
regain the natural balance of the intestinal flora, you may add to your
diet some friendly lactobacillus, acidophilus or other strains.
On the other hand, insomnia, floaters and flashies increase a lot with
natural antiinflammatories or vasoconstrictors like lecithin,
pinneaple, sugar and other substances that are good for the joints for
instance. Floxies seem to have a need for some joint nutritional
support to help with the deterioration and the pain. Substances like
MSM, glucosamine, and others are helpful in that sense but their
antiinflammatory activity increases vision problems (floaters and
ziggies), the neuropatic pains, the twitchings and the heart
arrythmias and also seems to delay muscular and soft tissue
recovery.
The contents of the next table are based in the experiences of about
40 floxies. Not all of them have tested all. Do not use it as a fixed
reference for yourself.
-Table 7- POSITIVE AND NEGATIVE EFFECTS

Oddly enough, there are very few floxies that do not react badly to
soy and its derivatives, specially if they are concentrated. Many
floxies show high IgG antibodies against phosphatidylcholine (soy)
and bromelain (pinneaple). It is uncertain wether they exhibited
those antibodies beforehand or it is just a consequence of the floxing.
In a first instance it might be considered wise to order a test for food
and supplement tolerance for every floxie. It consists of an analysis
of the IgG reactions to a hundred common foods and additives, so
that the floxie could know which ones release an IgG reaction,
because such reactions could exacerbate the floxing symptoms as
they would add more inmune complexes to the already burdened
blood vessels with the IgG and IgM complexes liberated after the
toxicity. However, trials done with a few floxies do not show
dramatic improvements if they avoid foods to which they are
intolerant (IgG reactive), evidencing that the drug induced inmune
reaction is of another order of magnitude with respect to food
intolerances. In any case, lecithin –found in soy and other foodscauses
very clear relapses and worsening of symptoms, but we have
not found yet the mechanism behind it.
Omega 3 oils help to overcome the stiffness, reduction in range of
motion of every joint, and decrease muscle pain. Grapes (seeds)
taken raw have positive effects in some mild and intermediate cases.
This is only a brief list of some of the most well known ones. There
are many other substances that could be rated based in our statistics,
included minerals, all the rest of vitamins, all aminoacids and many
other herbals, but it is beyond the scope of the current version of this
report. Each substance has its own therapeutic effects. Some should
not be taken together. In a future revision of this report an appendix
on details about these and other supplements could be added with the
point of view of the experiences of the floxies.
Remember:
These recommendations on supplements are only comments about
other’s experiences. Do not use them for planning your recovery.
Detoxifiying, chelating and cleansing treatments will not be
discussed here. This report does not cover either any treatment by
means of chemical drugs, metal compounds or the like. None of the
people that has collaborated in this report has undertaken any of
them.
PHYSICAL THERAPIES
Again, there are no magic silver bullet treatments and no total
agreement about how to treat pains and disabilities. Test the ones
that help you most in maintaining your fitness and well being.
Probably some of the following will help:
.. MECHANICAL: ultrasound; massage, especially deep massage
and with the aid of steel tools by a specialized practitioner;
stretching. They help with the regeneration, realignment of scar
tissue and removal of by-products of the reactions.
.. SUPPORTIVE: acupuncture; relaxation, meditation,
homeopathy, mesotherapy, gentle yoga.
.. EXERCISE: Especially controversial. For some it is positive
only after you feel you are getting out of the acute phase: biking
and swimming are preferred. Strengthening, especially
isometric exercises, and several sports and exercises, should be
introduced progressively. Somehow there is scattered evidence
that excessive exercise can induce new relapses, what needs
future clarification.

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
23/32
WATCH OUT FOR NEW PROBLEMS. YOUR BODY
IS NOT THE SAME
A floxed person is prone to suffer increased problems because the
severity of many common ailments is very much amplified by the
quinolone intoxication.
For instance, any time you get a virus or bacterial infection, a relapse
might be released, sometimes with extraordinary virulence. Your
quinolone- induced pains will increase a lot, and this situation may
last for many weeks after the clearance of the bug or infection.
As explained earlier, minor traumas take an abnormally long time to
recover. But a trauma on or near a floxed nerve is perhaps the worse
accident that a floxie can suffer. A floxed nerve is a nerve affected
by a quinolone-induced mononeuritis, even if the floxie had not
noticed clearly that the nerve was damaged with lesions. For
instance, the floxie can have a quinolone-induced femoral neuritis
but he thinks that his hip, gluteus and knee pains are just
neurological pains from the antibiotic but not related to that specific
nerve. If he suffers a blow on the quad that affects that nerve, the
femoral neuritis will worsen sharply, and recovery of that part of the
nervous system can take a few additional years of continuous and
sometime excruciating pains all along the upper leg.
The inactivity of the first months (acute phase) and above all, the
quinolone neuritis that affects muscles makes our muscles (lean
people) to atrophy. This makes things worst as our joints need as
much strength as possible in order to avoid misalignments, overuse,
and abuse of tendons.
For instance, without them realising it, some people, due to the
severe neuropathic intoxication, and after taking it very easy with
their Achilles tendons, experience atrophy of the tibialis anterior
muscle, the calves, the soleus and the main ruling muscles of the
lower leg and ankle. That submits the Achilles to further stress and
the vicious circle starts again, leaving the Achilles or other parts of
the ankle very disabled for years.
That is the reason why light weight work or isometric exercises are
essential once the acute phase has passed. In severe reactions, some
muscles fail to respond to strengthening exercises for at least 3 to 4
years, because the toxic neuritis that affects them makes any gain in
mass or performance impossible, irrespective of the workouts that
the floxie undertakes.
Many people that suffer severe reactions develop a for-life
intolerance to exercise. Any strenous activity or sport makes their
muscles ache for a long time and their whole body becomes quite
stiff. It is a very common permanent lesion caused by quinolone
antibiotics.
FOR ATHLETES ONLY
If you were an athlete or very active young or middle aged person,
you will resume your trajectory only if you have experienced a mild
reaction. Endurance will be severely curtained by an intermediate
reaction. After a severe reaction your athletic activities are
completely wiped out for the next five years or so, and only then will
you be in the position to attempt very exertional activities depending
on the level of permanent damage in joints and tissues that you have
sustained. In any case a severe reaction means the abrupt end of an
athletic existence.
There are very characteristic musculoskeletal lesions caused by
quinolones. Some times they are not the worst side effects, but are
big limitations for sports and cause enormous distress in young and
healthy athletes.
Cartilages are always affected. In intermediate reactions they
become softened and some get inflammed or start causing problems,
for instance in the spine, hips and knees. In severe reactions
cartilages become really eroded, and show up as different
osteoarthritis stages, from mild to advanced. Most affected are the
shoulder joint, hips, knees, and ankles, but also neck and spine.
Look at some of the musculoskeletal lesions that young and athletic
floxies had after unnoticed reactions to short courses of quinolones.
In all cases it has been demonstrated that they were quinoloneinduced
toxic reactions because after re-exposure to quinolones they
increased ten to a hundred times-fold in intensity.
.. Epicondylitis in tennis players. Toxic tendinitis.
.. Trochanteric bursitis (pain in the very tip of the hip bone).
.. Shin splints in runners and tennis players. Neurological collapse
of one or more of the tibialis complexes.
.. Plantar fasciitis. It was a toxic degradation of the muscle-tendon
complex.
.. Hamstrings pulls. It was a toxic femoral neuritis.
.. Posterior tibial tendon insuficiency.
.. Achilles tendinitis.
.. Anterior tibialis tendinitis.
.. Knee pains, lateral, medial and backside.
.. Many back problems.
.. Quads and tibialis muscle wasting.
.. Iliotibial band syndrome (toxic enthesitis).
.. Iliopsoas tendinitis.
.. Collagenous disorder in hips.
.. Rotator cuff tendinitis (shoulder)
.. Myositis, polymiositis.
.. Lactic acid build up.
.. Intolerance to exercise, lack of recovery.
Every athlete with a tendinitis or overuse syndrome, should be asked
wether he/she has taken quinolones during the last year, in order to
assess the diagnosis properly.
With normal fluoroquinolone treatments one week worth or so, the
strongest athlete will only experience a progressive diminished
capacity to recover after exercise. He will feel some soreness, and
stiffness some hours after his exertions. He will tend to think that it is
normal, since no other symptoms bother him and he soreness clears
up in a day or so.
With a few of such short treatments over the years, the athlete will
become marquedly rigid, specially in his legs. Unless he practices
stretching, he will not pay a lot of heed either.
If an athlete takes a prolonged course of fluoroquinolones, one of his
main nerves can become affected, for instance the tibialis anterior.
Then, the corresponding muscle gets wasted in a matter of a few
weeks. So all the stress needed to stabilize the ankle is posed in a
specific group of tendons (the tibialis posterior and flexor hallucis
longus for the pronators), that suddenly become completely crippled
and in the verge of rupturing. The athlete and their doctors become
alarmed. The latest order some 3-phase scans and other diagnosis
procedures and get to the wrong conclusion that the athlete suffers
from asymmetries, overuses, discrepancies, structural flaws or
others. Conventional treatments are instated. The only thing that

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
24/32
baffles everybody is the strangely long duration of the pains and
limitations. Nobody has had a clue about the real cause.
If an athlete has suffered a severe reaction, he losses the
functionnality of several joints or muscles. During the first months
he can feel pains and unability to exercise due to failure of one or
two joints. But as the months pass by, more joints add to the list of
incapacitating pains and limitations of the range of motion. The
athlete gets shocked because the list of joints involved is continuosly
increasing for up to 18 months and includes joints that he always had
considered rock solid, without a single complaint of the slightest
entity in the past. Normally, ankles, knees, hips, elbows, wrists, and
shoulders are involved.
It is a tragedy for the athlete. All his joints snap and make a lot of
noise when moving. Soon his knees and/or hips start grinding,
clicking and cranking, normally a sign of the erosion and destruction
of the cartilages. MRI’s prior and post quinolones in several athletes
have shown clearly those changes, even in athletes that have
refrained from exercise post floxing.
In severe reactions there is a marked weight loss, mainly muscle.
Workouts can do nothing to help recover the muscle mass, neither
any supplement, because the cause is neurologic.
After a severe reaction it takes between 3 years (for people in their
thirties) and 4 years (for people in their forties) to feel that their body
is starting to recover. Only then the athlete will be able to start a
slowly progressive program of exercises. He will feel little by little
that his flexibility, overall recovering capacity and level of pains, are
improving. The athlete will also have to fight to survive the rest of
symptoms affecting the heart, eyes, sinus, digestive system,
insomnia, neuropaties of all kinds, etcetera, because as you have read
above nearly all the organs of the body suffer disabling toxic lesions.
Every trainer, orthopedist, coach, physiotherapist and professionals
whose activities are related with sports should be aware of these
devastating effects of the quinolone antibiotics, and advise their
pupils to ask doctors for alternative antibiotics.
TREAT YOUR SELF FAIRLY
Allow yourself some treats. Do not blame your bad luck. Do not
submit yourself to excessively strict diets, programs or schedules.
In every phase, whenever you feel able or strong enough, try to get
in contact again with those activities that you enjoyed most before
being floxed.
TYPICAL ADVERSE REACTION LIST OF A
QUINOLONE ANTIBIOTIC
The following is the list of typical reactions observed during quinolone
therapy. The list is the official one. It is comprehensive, but does not mention
the severity of the reactions, and also, the percentage of people affected has
been manipulated to appear as very low, when indeed it is much higher.
Underlined are the reactions experienced by people related with this report.
Pregnancy Risk Factor and Implications: Category C, is excreted
in human milk, potential for serious adverse reactions in nursing
infants.
Contraindications: Do not use if you have a known allergy to
ciprofloxacin or to any member of the quinolone class of
antimicrobial agents.
Warnings/Precautions: The safety of this drug in pediatric patients,
people less than 18 years old, pregnant and lactating women has not
been established. This drug may cause cartilage erosion of weightbearing
joints. This drug may also cause convulsion, intracranial
pressure, toxic psychosis, and it may cause central nervous system
events. Use with caution in patients with CNS disorders or in
patients with risk factors such as certain drug therapies and renal
dysfunction that may predispose them to seizure or lower their
seizure threshold. Serious and fatal reactions have been reported in
patients receiving concurrent administration of ciprofloxacin and
theophylline. Serious and occasionally fatal hypersensitivity
reactions have been reported in patients receiving quinolone therapy.
Severe hypersensitivity reactions characterized by rash, fever,
eosinophilia, jaundice, and hepatic necrosis with fatal outcome have
also been rarely reported in patients receiving ciprofloxacin along
with other drugs. Psuedomembranous colitis has been reported with
nearly all antibacterial agents including ciprofloxacin, and may
range in severity from mild to life-threatening. Treatment with
antibacterial agents alters the normal flora of the colon. Achilles and
other tendon ruptures that required surgical repair or resulted in
prolonged disability have been reported with ciprofloxacin and other
quinolones. Avoid excessive sunlight as moderate to severe
phototoxicity manifested as an exaggerated sunburn reaction has
been observed in some patients while on the quinolone class of
drugs.
Adverse Reactions: At least 5% experienced: Nausea
Adverse Reactions: Less than 5% experienced: Diarrhea, vomiting,
abdominal pain/discomfort, headache, restlessness, rash, palpitation,
atrial flutter, ventricular ectopy, syncope, hypertension, angina
pectoris, myocardial infarction, cardiopulmonary arrest, cerebral
thromobosis, dizziness, lightheadedness, insomnia, nightmares,
hallucinations, manic reaction, irritability, tremor, ataxia, convulsive
seizures, lethargy, drowsiness, weakness, malaise, anorexia, phobia,
depersonalization, depression, paresthesia, painful oral mucous, oral
candidiasis, dysphagia, intestinal perforation, gastrointestinal
bleeding, cholestatic jaundice, arthralgia or back pain, joint stiffness,
achiness, neck or chest pain, flare up of gout, interstitial nephritis,
nephritis, renal failure, polyuria, urinary retention, urethral bleeding,
vaginitis, acidosis, dyspnea, epistaxis, laryngeal or pulmonary
edema, hiccough, memophysis, bronchospase, pumonary embolism,
pruritus, urticaria, photosensitivity, flushing, fever, chills,
angioedema, edema of the face, neck, lips, conjuctivae or hands,
cutaneous candidiasis, hyperpigmentation, erythera nodosum,
blurred vision, disturbed vision, decreased visual acuity, diplopia,
eye pain, tinnitus, hearing loss, bad taste, vaginitis, headache,
vaginal pruritus, abdominal discomfort, lymphadenopathy, foot pain,
dizziness, breast pain, nausea, diarrhea, central nervous system
disturbance, abnormalities of liver associated enzymes, eosinophila,
restlessness, rash, cardiovascular collapse, cardiopulmonary arrest,
myocardial infarction, arrhythmia, tachycardia, palpitation, cerebral
thrombosis, syncope, cardiac murmur, hypertension, hypotension,
angina pectoris, convulsive seizures, paranoia, toxic psychosis,
depression, dysphasia, phobia, depersonalization, manic reaction,
unresponsiveness, ataxia, confusion, hallucinations, dizziness,
lightheadedness, paresthesia, anxiety, tremor, insomnia, nightmares,
weakness, drowsiness, irritability, malaise, lethargy, ileus, jaundice,
gastrointestinal bleeding, C. difficle associated diarrhea,
pseudomembranous colitis, pancreatitis, hepatic necrosis, intestinal
perforation, dyspepsia, epigastric or abdominal pain, vomiting,
constipation, oral ulceration, oral candidiasis, mouth dryness,
anorexia, dysphagia, flatulence, thrombophlebitis, burning, pain,

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
25/32
pruritus, paresthesia, erythema, swelling, arthralgia, jaw, arm or back
pain, joint stiffness, neck and chest pain, achiness, flare up of gout,
renal failure, intarstitial nephritis, hemorrhagic cystitis, renal calcuti,
frequent urination, acidosis, urethral bleeding, polyuria, urinary
retention, gynecomastia, candiduria, vaginitis. Crystalluria,
cylindruria, hematuria, and albuminutia have also been reported,
respiratory arrest, pulmonary embolism, dyspnea, pulmonary edema,
respiratory distress, pleural effusion, hemoptysis, epistaxis,
hiccough, anaphylactic reactions, erythema multiforme/Stevens-
Johnson syndrome, exfoliative dermatitis, toxic epidermal
necrolysis, vasculitis, angioedema, edema of the lips, face, neck,
conjunctivae, hands or lower extremities, purpura, fever, chills,
flushing, pruritus, urtigaria, cutaneous candidiasis, vesicles,
increased perspiration, hyperpigmentation, erythema nodosum,
photosensitivity. Allergic reactions ranging from urticaria to
anaphylactic reactions have been reported. Also experienced were
decreased visual acuity, blurred vision, disturbed vision (flashing
lights, change in color perception, overbrightness of lights, diplopia),
eye pain, anosmia, hearing loss, tinnitus, nystagmus, a bad taste,
agranulocytosis, prolongation of prothrombin time, and possible
exacerbation of myasthenia gravis, change in serum phenytoin,
postural hypotension, vasculitis, agitation, confusion, delirium,
dysphasia, myoclonus, nystagmus, toxic psychosis, constipation,
dyspepsia, flatulence, hepatic necrosis, jaundice, pancreatitis,
pseudomembranous colitis. (The onset of pseudomembranous colitis
symptoms may occur during or after antimicrobial treatment.),
agranulocytosis, hemolytic anemia, methemaglobinemia,
prolongation of prothrombin time, elevation of serum triglycerides,
cholesterol, blood glucose, serum potassium, myalgia, possible
exacerbation of myasthenia gravis, tendinitis/tendon rupture,
albuminuria, candiduria, renal calculi, vaginal candidiasis,
anaphylactic reactions, erythema multiforme/Stevens-Johnson
syndrome, exfoliative dermatitis, toxic epidermal necrolysis,
anosmia, taste loss.
BIBLIOGRAPHY-REFERENCES
We have consulted nearly 5.500 abstracts, summaries and full articles about
quinolone’s adverse effects. We have purchased the right to access some
medical reports. Here you can find some references.
1. Arthritis induced by norfloxacin. Jeandel et al (J Rheumatol 1989 )
2. Rheumatolgical side effects of quinolones. Ribard et al (Baillere’s Clin
Rheumatol 1991 5 175-191)
3. Bailey RR, Kirk JA, Peddie BA. Norfloxacin-induced rheumatic disease. N Z
Med J 1983; 96:590.
4. Fluoroquinolone induced tendinopathy; what do we know? Harrell et al
(South Med J 92(6) 622-625 1999)
5. Quinolone and Tendon Ruptures. Casperian et al (Southern Medical Journal
May 2000 vol 93 no 5 pages 488-491)
6. Adverse reactions to fluoroquinolones an overview on mechanistic aspects.
De Sarro et al (Current MedicinZhanel GG, Walkty A, Vercaigne L, et al.
Fluoroquinolones in Canada: a critical review. Can J Infect Dis 1999;
7. Achilles tenditinis and tendon rupture due to fluoroquinolone therapy. Huston
et al (New England Journal of Medicene 1994 331 748)
8. A case of destructive polyarthropathy in a 17-year-old youth following
pefloxacin treatment. Chevalier X, Albengres E, Voisin MC, Tillement JP,
Larget-Piet B. Drug Saf 1992;7:310-14.
9. Features of tendon disorders with fluoroquinolones. Royer et al (Therapie
1994 49 75-76)
10. Van der Linden PD, van der Lei J, Nab HW, Knol A, Stricker BHC. Achilles
tendonitis associated with fluoroquinolones. Br J Clin Pharmacol 1999;
11. Carrasco JM. Tendonitis associated with ciprofloxacin. Ann Pharmacother
1997; 31:120.
12. McEwan SR, Davey PG. Ciprofloxacin and tenosynovitis. Lancet 1988;
13. Norfloxacin induced arthalgia. Terry et al (J Rheumatol 1995 22 793-
14. Zabraniecki L, Negrier I, Vergne P, et al. Fluoroquinolone induced
tendinopathy: report of 6 cases. J Rheumatol 1996; 23:516-20.
15. Le Huec JC, Schaeverbeke T, Chauveaux, Rivel J, Dehais J, Le Rebeller A.
Epicondylitis after treatment with fluoroquinolone antibiotics. J Bone Joint
Surg Br 1995; 77:293-5.
16. Hayem G, Carbon C. A reappraisal of quinolone tolerability: the experience of
their musculoskeletal adverse effects. Drug Saf 1995;13:338-42.
17. Burkhardt JE, Waterspiel JN, Schaad UB. Quinolone arthropathy in animals
versus children. Clin Infect Dis 1997;25:1196-1204.
18. Jorgensen C, Anaya JM, Didry C, et al. Arthropathies et tendinopathie
achillénne induites par la péfloxacine. Rev Rhum Mal Osteoartic 1991;
19. Beuchard J, Rochcongar P, Saillant G, et al. Tendinopathie achillénne
bilatérale chronique à la péfloxacine, sans rupture spontanée, traitée
chirurgicalement. Presse Med 1996; 25:1083.
20. Meyboom RHB, Olsson S, Knol A, et al. Achilles tendonitis induced by
pefloxacin and other fluoroquinolone derivatives. Pharmacoepidemiology and
Drug Safety 1994; 3:185-9.
21. Blanche P, Sereni D, Sicard D, et al. Tendinopathies achillénnes induites par
la péfloxacine: a propos de 2 cas. Ann Med Interne (Paris) 1992;
22. Ribard P, Audisio F, Kahn MF, et al. Seven Achilles tendonitis including 3
complicated by rupture during fluoroquinolone therapy. J Rheumatol 1992.
23. Cohen de Lara A, Rosenberg F, Struz P. Trois nouveau cas de tendinopathie
achillénne après traitement par fluoroquinolones. Rev Rhum Mal Osteoartic
1992; 59:652.
24. Franck JL, Bouteiller G, Chagnaud P, et al. Ruptures des tendons d'Achille
chez deux adultes traités par péfloxacine d'ont un cas bilatéral. Rev Rhum
Mal Osteoartic 1991; 58:904.
25. Mirovsky Y, Pollack L, Arlazoroff A, et al. Ciprofloxacin-associated bilateral
acute Achilles tendonitis [in Hebrew] [abstract]. Harefuah 1995;
26. Dekens-Konter JA, Knol A, Olsson S, et al. Tendonitis of the Achilles tendon
caused by pefloxacin and other fluoroquinolone derivatives [in Dutch]. Ned
Tijdschr Geneeskd 1994; 139:528-31.
27. Movin T, Gad A, Güntner P, Földhazy, Rolf C. Pathology of the Achilles
tendon in association with ciprofloxacin treatment. Foot Ankle Int 1997;
28. McGarvey WC, Singh D, Trevino SG. Partial Achilles tendon ruptures
associated with fluoroquinolone antibiotics: a case report and literature
review. Foot Ankle Int 1996; 17:496-8.
29. Poon CCH, Sundaram NA. Spontaneous bilateral Achilles tendon rupture
associated with ciprofloxacin. Med J Aust 1997; 166:665.
30. West MB, Gow P. Ciprofloxacin, bilateral Achilles tendonitis and unilateral
tendon rupture a case report. N Z Med J 1998; 111:189.
31. Lee TW, Collins JF. Ciprofloxacin associated bilateral Achilles tendon
rupture. Aust N Z J Med 1992; 22:500.
32. Boulay I, Farge D, Haddad A, et al. Tendinopathie à la ciprofloxacine avec
possibilité de rupture partielle du tendon d'Achille. Ann Med Interne (Paris)
1993; 144:.
33. Hernández MV, Peris P, Sierra J, et al. Tendinitis por fluoroquinolonas:
descripción de dos pacientes. Med Clin (Barc) 1994; 103.
34. Jagose JT, McGregor DR, Nind GR, Bailey RR. Achilles tendon rupture due
to ciprofloxacin. N Z Med J 1996; 109:.
35. Petersen W, Laprell H. Insidious rupture of the Achilles tendon after
ciprofloxacin-induced tendinopathy: a case report [in German] [abstract].
Unfallchirurgie 1998;
36. Cattaneo F, Serna M, Stoller R. Fluoroquinolone associated tendon rupture
and bilateral tendinitis in a hemodialysis patient and two renal transplant
recipients. Kidney Int 1990; 50:1429.
37. Chaslerie A, Bannwarth B, Landreau JM, Yver L, Begaud B. Ruptures
tendineuses et fluoro-quinolones: un effet indésirable de classe. Rev Rhum
Mal Osteoartic 1992; 59:297-8.
38. Tonolli-Serabian I, Mattei JP, Poet JL, et al. Rupture de al coiffe des
rotateurs au cours d'un traitement par quinolone. Collection de Pathologie
Locomotrice 1993; 26:147-50.
39. Schwald N, Debray-Meignan S. Suspected role of ofloxacin in a case of
arthralgia, myalgia, and multiple tendinopathy. Rev Rhum Engl Ed 1999;
40. Huston KA. Achilles tendonitis and tendon rupture due to fluoroquinolone
antibiotics. N Engl J Med 1994; 331:748.
41. Lewis JR, Gums JG, Dickensheets DL. Levofloxacin-induced bilateral
Achilles tendonitis. Ann Pharmacother 1999; 33:.
42. Borderie P, Marcelli C, Leray H, et al. Ruptures spontanees du tendon
d'Achille apres transplantation renale: role favorisant des fluoroquinolones
[abstract E22]. Rev Rhum 1992; 59:652.
43. Gabutti L, Stoller R, Marti HP. Fluoroquinolone as etiology of tendinopathy [in
German] [abstract]. Ther Umsch 1998; 55:558-61.
44. Gillet P, Blum A, Pierfitte C, et al. Fluoroquinolone-associated Achille's

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
26/32
tendonitis: MRI findings [abstract B128]. Arthritis Rheum 1993; 36:5163.
45. Perrot S, Kaplan G, Ziza JM. 3 cas de tendinite Achilléenne sous péfloxacine
d'ont deux avec rupture [in French] [letter]. Rev Rhum Mal Osteoartic 1992;
59:162.
46. Fleisch F, Hartmann K, Kuhn M. Fluoroquinolone-induced tendinopathy: also
occurring with levofloxacin. Infection 2000; 28:256-7.
47. Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin,
ofloxacin, azithromycin, and cefixime examined by observational cohort
studies. Br J Clin Pharmacol 1996; 41:277-84.
48. Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie
1996; 51:419-20.
49. Donck JB, Segaert MF, Vanrenterghem YF. Fluoroquinolones and Achilles
tendinopathy in renal transplant recipients. Transplantation 1994;
50. Royer RJ, Pierfitte C, Netter P. Features of tendon disorders with
fluoroquinolones. Therapie 1994; 49:75-6.
51. Waterston SW, Maffulli N, Ewen WB. Subcutaneous rupture of the Achilles
tendon: basic science and some aspects of clinical practice. Br J Sports Med
1997; 31:285-98
52. Lafon M. Tendinopathies et fluoroquinolones. Concours Med 1993;
53. Ruptures spontanées du tendon d'Achille après transplantation rénale: rôle
des fluoroquinolones. Presse Med 1993. Leray H, Mourad G, Chong et al.
54. Price AE, Evans PM, Waugh TR. Bilateral simultaneous Achilles tendon
ruptures: a case report and review of the literature. Clin Orthop 1986;
55. Achilles tendon lesions in sport. Sports Med 1986; 3:114-35. Williams JGP.
56. Simonin MA, Gegout-Pottie P, Minn A, et al. Pefloxacin-induced Achilles
tendon toxicity in rodents: biochemical changes in proteoglycan synthesis
and oxidative damage to collagen. Antimicrob Agents Chemother 2000;
44:867-72.
57. Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats:
comparison of toxicities of 10 fluoroquinolones and effects of antiinflammatory
compounds. Antimicrob Agents Chemother 1997. Kashida Y,
Kato M.
58. Tendons and fluoroquinolones: unresolved issues. Rev Rhum Engl Ed 1997;
64:437-9. Kahn MF, Hayem G.
59. Histologic and Histochemical Changes in Articular Cartilages of Immature
Beagle Dogs Dosed with Difloxacin, a Fluoroquinolone. J.E. Kurkhardt et al
(Vet Pathol 27;162-170, 1990)
60. Magnesium Deficiency Induces Joint Cartilage Lesions in Juvenile Rats
which are Identical to Quinolone Induced Arthropathy. Stahlmann et al
(Antimicrobial Agents and Chemotherapy, Sept., 1995 pg 2013-2018)
61. Quinolone induced cartilage lesions are not reversible in rats. Forster et al
(Arch Toxicol (1996) 70; 474-481)
62. Toxic effects of quinolone antibacterial agents on the musculoskeletal system
in juvenile rats. Yoko Kashida et al (Toxicologic Pathology vol 25 number 6
pages 635-643 1997)
63. Evaluation of toxicokinetic variables and arthropathic changes in juvenile
rabbits after oral administration of an ivestigational fluoroquinolone, pd
117596 Johnson et al (AJVR vol 61 no 11, November 2000)
64. Nalidixic Acid arthralgia. Bailey et al (CMA Journal 1972; 107 601-605)
65. Jouirland JP Les ruptures tendineusues. Le tendon normal et patholoqique.
Seminar de Monte Carlo 13-14 February 1976
66. Between 1985 and July 1992 100 cases of tendon disorders had been
identified in France. Kessler et al (HRG Publication 1399, 1996)
67. Seven Achilles tendinitis including three complicated by rupture during
fluoroquinolone therapy. Ribard et al (J Rheumatol 1992; 19; 1479-1481)
68. Spontaneous bilateral rupture of the Achille’s tendon in a renal transplant
recipient. Mainard et al (Nephron 1993;65- 491-492)
69. Fluoroquinolone Induced Tenosynovitis of the Wrist mimicking de Quervain’s
Disease. Gillet et al (British Journal of Rheumatology Feb 1995)
70. Tendon disorders with fluoroquinolones 421 cases have been collected by
the Centre de Pharmacovigilance, 340 of tendinitis and 81 cases of tendon
rupture. Therapie 1996; 51: 419-420
71. Fluoroquinolone induced arthralgia and Magnetic Resonance Imaging.
Loeuille et al (The Journal of Rheumatology, July 1996)
72. Fluoroquinolone Induced Tendinopathy; Report of Six Cases. Zabraniedkl et
al (The Journal of Rhuematology 1996; 23; 3)
73. Tendons and Fluoroquinolones; Unresolved issues. Kahn et al (Rev Rhum
[Engl. Ed.] 1997 64(7-9) 437-439). (Rev Rhum [Ed. Fr.] 1997
74. Fluoroquinolones tendinitis update Australia
75. Tendinitis associated with Fluoroquinolone therapy. (Pharmaceuticals
Newsletters Nos 7&8 July & August 1997)
76. Tendinitis and tendon rupture with fluoroquinolones. ADRAC (The Achilles
heel of fluoroquinolones Aust Adv Drug React Bull 1997, Szarfman et al)
77. Effects of Ciprofloxacin and Ofloxacin on adult human cartilage in vitro.
(Antimicrob Agents Chemother 1997
78. Repeated rupture of the extensor tendons of the hand due to
fluoroquinolones, Apropos of a case. Levadoux et al (Ann Chir Main Memb
Super 1997, vol 16, issue 2, pgs 130-133).
79. Inhibition of fibroblast metabolism by a fluoroquinolone antibiotic. Williams et
al (American Academy of Orthopedic Surgeons, 1999 Annual meeting, paper
number 118, Geb 5, 1999)
80. Fluoroquinolone induced tendinopathy; also occurring with levofloxacin.
Fleisch et al (Infection 28 2000 no 4 pages 256-257)
81. Levofloxacin induced bilateral achilles tendinitis. Lewis et al (The Annals of
Pharmacotherapy 1999 July/August, volume 33 pages 792-795)
82. al Chemistry 2001, 8, 371-384)
83. Fluoroquinolone use and the change in incidence of tendon rupture in the
Netherlands. Van der Linden et al (Pharmacy World and Science 2001
84. Tendon disorders attributed to fluoroquinolones; a study on 42 spontaneous
reports in the period 1988-1998. Van Der Linden et al (American College of
Rheumatology; Arthritis Care and Research 45; 2001 pages 235-239).
85. Adverse drug reactions to fluoroquinolones at a tertiary care hospital in
northern India. Uppal,R.; Jhaj,R.; Malhotra,S. J Assoc Physicians India 1998
; VOL 46; ISSUE 11; 946-947.
86. Fluorine level in the bone and cartilage in children treated with ciprofloxacin
(data obtained from the femur distal part. [Article in Russian]. Postnikov SS,
Kamenev AI, Viter IP, Semykin SI, Kapranov NI, Nazhimov VP. Russian
State Medical University, Moscow.
87. Effects of ciprofloxacin and ofloxacin on adult human cartilage in vitro.
Menschik M, Neumuller J, Steiner CW, Erlacher L, Koller M, Ullrich R,
Graninger W, Graninger WB. Department of Internal Medicine III, University
of Vienna, Vienna-Oberlaa, Austria.
88. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast
metabolism. Williams RJ III, Attia E, Wickiewicz TL, Hannafin JA. Laboratory
for Soft Tissue Research, Sports Medicine & Shoulder Service, Hospital for
Special Surgery, New York, New York, USA.
89. Schaad UB, Wedgewood-Kruko J. Nalidixic acid in children: retrospective
matched controlled study for cartilage toxicity. Infection 1987;15:165-8.
90. Schaad UB, Stoupis C, Wedgewood J, Tschaeppeler H, Vock P. Clinical,
radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric
patients with cystic fibrosis receiving a three-month course of ciprofloxacin.
Pediatr Infect Dis J 1991;10:723-9.
91. Schaad UB, Sander E, Wedgewood J, Schaffner T. Morphologic studies for
skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic
fibrosis patients. Pediatr Infect Dis J 1992;11:1047-9.
92. Fluoroquinolone's Effect on Growth of Human Chondrocytes and
Chondrosarcomas: In Vitro and In Vivo Correlation Scientific Exhibitor Rooms 10
93. The comparative arthropathy of fluoroquinolones in dogs. Takizawa,T.;
Hashimoto,K.; Minami,T.; Yamashita,S.; Owen,K.
94. [Repeated rupture of the extensor tendons of the hand due to
fluoroquinolones. Apropos of a case] Levadoux,M.; Carli,P.; Gadea,J.F.; De
Mauleon De Bruyere,P.; Perre,C.
95. Effects of ciprofloxacin and ofloxacin on adult human cartilage in vitro.
Menschik M, Neumuller J, Steiner CW, Erlacher L, Koller M, Ullrich R,
Graninger W, Graninger WB. Department of Internal Medicine III, University
of Vienna, Vienna-Oberlaa, Austria.
96. AndersonME, Mazur A, Yang T, et al. Potassium current antagonist
properties and proarrhythmic consequences of quinolone antibiotics. J
Pharmacol Exp Ball P. Quinolone-inducted QT interval prolongation: a not so
unexpected class effect. J Antimicrob Chemother. 2000;45:557-
97. Ball P. Quinolone-inducted QT interval prolongation: a notsounexpected
class effect. J Antimicrob Chemother. 2000;45:557-559.
98. Bertino JS, Owens RC, Carnes TD, et al. Gatifloxacin-associated corrected
QT interval prolongation, torsades de pointes, and ventricular fibrillation in
patients with known risk factors. Clin Infect Dis. 2002
99. Conder ML, Lawrence JH, Levesque PC, Blanar MA. Inhibition of the HERG
potassium ion channel by fluoroquinolone antibiotics: correlation with the risk
for clinically significant QT interval prolongation [abstr]. In: Program and
abstracts of the 40th interscience conference on antimicrobial agents and
chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000.
100. Committee for Proprietary Medicinal Products. Points to Consider: The
Assessment of the Potential for QTc Interval Prolongation by Non

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
27/32
Cardiovascular Medicinal Products. London: The European Agency for
Evaluation of Medicinal Product; 1997.
101. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin,
ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy.
2001;21(12):1468-1472.
102. Grasela D, Lacreta F, Uderman H, Kollia G, Birkhofer M. A dose-escalation
study of the safety, tolerance, and pharmacokinetics of intravenous
gatifloxacin in healthy adult subjects [abstr]. In: Program and abstracts of the
39th interscience conference on antimicrobial agents and chemotherapy,
San Francisco, September 26-29, 1999.
103. Hollister AS, Haverstock D, Choudhri S. Moxifloxacin has a favorable
cardiovascular safety profile in patients taking concomitant QTc prolonging
drugs [abstr]. In: Program and abstracts of the 40th interscience conference
on antimicrobial agents and chemotherapy, Toronto, Ontario, Canada,
September 17-20, 2000.
104. Interactions of a series of fluoroquinolone antibacterial drugs with the human
cardiac K(+) channel. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D
Aventis Pharmaceuticals, Inc. Bridgewater, New Jersey.
105. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic
and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother
1996;37(suppl A):161-7.
106. Kang J, Wang J, Chen XL, et al. Interactions of a series of fluoroquinolone
antibacterial drugs with the human cardiac K+ channel HERG. Mol
Pharmacol. 2001;59:122-126.
107. Lannini PB, Circiumaru I. Gatifloxacin-induced QTc prolongation and
ventricular tachycardia. Pharmacotherapy. 2001;21: 361-362
108. Lannini PB, Circiumaru J, Byazrova E, et al. QTc prolongation associated
with levofloxacin. Br Med J. 2001;7277:46-47.
109. Lannini, M.D., Department of Medicine, Danbury Hospital, Danbury,
Connecticut; and Glenn S. Tillotson, M.Sc., FRSM, Evaluating the Risk of
Cardiac Toxicity. Public Health Research Institute, New York University, New
York, New York
110. Noel GJ, Abels R, Minton N, et al. Effect of three fluoroquinolones (FQs) on
QTc intervals in healthy volunteers. Interscience Conference on Antimicrobial
Agents and Chemotherapy. Washington, DC: American Society for
Microbiology; 2001:24-24.
111. Owens RC. Risk assessment for antimicrobial agent-induced QTc interval
prolongation and torsades de pointes. Pharmacotherapy. 2001.
112. Owens RC, Ambrose PG. Torsades de pointes associated with
fluoroquinolones. Pharmacotherapy. 2002;22(5):663-67
113. Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob
Chemother. 2002;49:593-596.
114. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy
2002 May;22(5):663-8; discussion 668-72. Owens RC Jr, Ambrose PG.
Department of Clinical Pharmacy, Maine Medical Center, Portland, USA.
115. Shah RR. The significance of QT interval in drug development. J Clin
Pharmacol. 2002;54:188-202.
116. Samaha FF. QTc prolongation and polymorphic ventricular tachycardia in
association with levofloxacin. Am J Med 1999;107:528-9.
117. Schaffer D, Singer S, Korvick J. Macrolide and fluoroquinolone associated
torsades de pointes: a review of the FDA adverse event reported system.
Abstracts of the 41st Interscience Conference on Antimicrobial Agents and
Chemotherapy.: American Society for Microbiology; 2001.
118. Patricia M Moore. Vasculitic neuropathies.University of Pittsburgh,
Department of Neurology
119. Nephrotoxicity and purpura associated with levofloxacin. Famularo G, De
Simone C. Giuseppe Famularo MD PhD, Clinical Specialist, Department of
Internal Medicine, San Camillo Hospital, Rome, Italy.
120. Cutaneous adverse reaction to ciprofloxacin: demonstration of specific
lymphocyte proliferation and cross-reactivity to ofloxacin in vitro. Ronnau AC,
Sachs B, von Schmiedeberg S, Hunzelmann N, Ruzicka T, Gleichmann E,
Schuppe HC. Medical Institute of Environmental Hygiene at Heinrich-Heine-
University, Department of Dermatology, Duesseldorf, Germany.
121. Bruce IN, Bell AL. A comparison of two nomenclature systems for primary
systemic vasculitis. Br J Rheumatol 1997;36:453-458
122. Cid MC. New developments in the pathogenesis of systemic vasculitis. Curr
Opin Rheumatol 1996;8:1-11
123. Cid MC, Kleinman HK, Grant DS, et al. Estradiol enhances leukocyte binding
to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in
TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule
type 1, and vascular cell adhesion molecule type 1. J Clin Invest 1994;
124. Dyck PJ, Conn DL, Okazaki H. Necrotizing angiopathic neuropathy: threedimensional
morphology of fiber degeneration related to sites of occluded
vessels. Mayo Clin Proc 1972;47:461-475
125. Ferri C, La Civita L, Cirafisi C, et al. Peripheral neuropathy in mixed
cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol
1992
126. Fujimura H, Lacroix C, Said G. Vulnerability of nerve fibres to ischaemia. A
quantitative light and electron microscope study. Brain 1991;114:1929-1942
127. Kiely PD, Pecht I, Oliveira DB. Mercuric chloride-induced vasculitis in the
brown Norway rat: 0 0 T cell-dependent and -independent phases: role of
the mast cell. J Immunol 1997;159:5100-5106
128. Kissel JT, Riethman JL, Omerza J, et al. Peripheral nerve vasculitis: immune
characterization of the vascular lesions. Ann Neurol 1989;25:291-297
129. Kumazawa K, Sobue G, Aizawa I, et al. Autonomic dysfunction in vasculitic
neuropathy, special reference to sudomotor function. (In Japanese.) Rinsho
Shinkeigaku 1990;30:599-604
130. Lhote F, Cohen P, Genereau T, et al. Microscopic polyangiitis: clinical
aspects and treatment. Ann Med Interne (Paris) 1996;147:165-177
131. Marceau F. Evidence for vascular tone regulation by resident or infiltrating
leukocytes. Biochemical Pharmacology 1996;52:1481-1488
132. Moore PM. Neurological manifestation of vasculitis: update on
immunopathogenic mechanisms and clinical features. Ann Neurol
1995;37:(suppl 1):S131-S141
133. Nowack R, Flores-Suarez LF, van der Woude FJ. New developments in
pathogenesis of systemic vasculitis. Curr Opin Rheumatol 1998
134. Olney RK. Neuropathies associated with connective tissue disease. Semin
Neurol 1998;18:63-72
135. Panegyres PK, Faull RJ, Russ GR, et al. Endothelial cell activation in
vasculitis of peripheral nerve and skeletal muscle. J Neurol Neurosurg
Psychiatry 1992;55:4-7
136. Satoi H, Oka N, Kawasaki T, et al. Mechanisms of tissue injury in vasculitic
neuropathies. Neurology 1998;50:492-496
137. Schnaper HW, McGowan KA, Kim-Schulze S, et al. Oestrogen and
endothelial cell angiogenic activity. Clin Exp Pharmacol Physiol 1996
138. Tervaert JW, Kallenberg CG. Cell adhesion molecules in vasculitis. Curr Opin
Rheumatol 1997;9:16-25
139. Wagner AD, Bjornsson J, Bartley GB, et al. Interferon- 0-producing T cells
in giant cell vasculitis represent a minority of tissue-infiltrating cells and are
located distant from the site of pathology. Am J Pathol 1996;148:1925-1933
140. Watts RA, Carruthers DM, Scott DG. Epidemiology of systemic vasculitis:
changing incidence or definition? Semin Arthritis Rheum 1995;25:28-34
141. Weyand CM, Wagner AD, Bjornsson J, et al. Correlation of the topographical
arrangement and the functional pattern of tissue-infiltrating macrophages in
giant cell arteritis. J Clin Invest 1996;98:1642-1649
142. Peripheral Neuropathy Associated with Fluoroquinolones. The Annals of
Pharmacotherapy 2001 December, Volume 35 1. Jay S Cohen.
143. Peripheral neuropathy associated with fluoroquinolones (letter). Lancet 1992.
Aoun M, Jacquy C, Debusscher L, Bron D, Lehert M, Noel P, et al.
144. Effects of quinolones on the central nervous system. In: Hooper DC, Wolfson
JS, eds.
145. Central nervous system toxicity of quinolones: human and animal findings. J
Antimicrob Chemother 1990;26(suppl B):219-25. Christ W.
146. Potential interactions of the extended-spectrum fluoroquinolones with the
CNS. Drug Saf 1999;21:123-35. Lode H.
147. Schmuck G, Schurmann A, Schlüter G. Determination of the excitatory
potencies of quinolones in the central nervous system by an in vitro model.
Antimicrob Agents Chemother 1998; 42: 1831-6.
148. Seizures Associated with Fluoroquinolones. The Annals of
Pharmacotherapy: Vol. 36, No. 7, pp. 1162–1167. Janine M Kushner,
Howard J Peckman, and Clyde R Snyder.
149. Potential neurologic toxicity related to cipro-floxacin. Schwartz MT, Calvert
JF. DICP 1990;24:138- 40.
150. Peripheral sensory disturbances related to treatment with
fluoroquinolones.Hedenmalm K, Spigset O. J Antimicrob Chemother 1996.
151. Fluoroquinolone antibiotics block neuromuscular transmission. Neurology
1998;50:804-7. Sieb JP.
152. Prevention and management of drug-induced peripheral neuropathy. Drug
Saf 1991;6:302-14. Olesen LL, Jensen TS.
153. Seizures associated with ofloxacin therapy.Traeger SM, Bonfiglio MF, Wilson
JA, Martin BR, Nackes NA. Clin Infect Dis 1995;21: 1504-6.
154. Neurotoxicity of antibacterial therapy. South Med J 1994; Thomas RJ.
155. Trovafloxacin-induced weakness due to a demyelinating polyneuropathy.

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
28/32
South Med J 2000;93:514-5. Murray CK, Wortmann GW.
156. Neurologic adverse effects during concomitant treatment with ciprofloxacin,
NSAIDs, and chloroquine: possible drug inter-action. Ann Pharmacother.
1993;27:1058-9. Rollof J, Vinge E.
157. The Annals of Pharmacotherapy: Vol. 36, No. 9, pp. 1380–1382.
Nephrotoxicity and Purpura Associated with Levofloxacin. Giuseppe
Famularo and Claudio De Simone.
158. What is Peripheral Neuropathy?. Office of Communications and Public
Liaison. National Institute of neurological Disorders and Stroke. National
Institutes of Health. Bethesda, MD 20892
159. Effects of fluoroquinolones on the locomotor activity in rats. Thiel, R.;
Metzner, S.; Gericke, C.; Rahm, U.; Stahlmann, r. archives of toxicology
2001; vol 75; part 1.
160. [Neuropsychiatric manifestations and quinolones. Apropos of a case] [Article
in French] Rampa S, Caroli F. l'Hopital Sainte-Anne, Paris.
161. Selective antagonism of the GABA(A) receptor by ciprofloxacin and
biphenylacetic acid. Green MA, Halliwell RF. Department of Pharmacology,
School of Health Sciences, University of Sunderland.
162. Kawakami J, Yamamoto K, Asanuma A, Yanagisawa K, Sawada Y, Iga T.
Inhibitory effect of new quinolones on GABAA receptor-mediated response
and its potentiation with felbinac in Xenopus oocytes injected with mousebrain
mRNA: correlation with convulsive potency in vivo. Toxicol Appl
Pharmacol 1991; 145: 246-54.
163. Ciprofloxacin-induced acute psychosis. Urology 1995;46:102-3. Mulhall JP,
Bergmann LS.
164. Akahane K, Kato M, Takayama S. Involvement of inhibitory and excitatory
neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in
mice. Antimicrob Agents Chemother, 1993;37:1764-1770.
165. Anastasio GD, Menscer D, Little JM. Norfloxacin and seizures. Ann Intren
Med 1988; 109: 169-70.
166. Barohn RJ. Approach to peripheral neuropathy and neuronopathy. Semin
Neurol. 1998;18:7-18.
167. Christ W. Central nervous system toxicity of quinolones: human and animal
findings. J Antimicrob Chemother 1990;26(suppl B):219-25.
168. Delon A, Bouquet S, Huguet F, Brunet V, Courtois P, Couet W.
Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of
fluoroquinolones in rats. Antimicrob Agents Chemother 1999; 43: 1511-5.
169. De Sarro A, Cecchetti V, Fravolini V, Naccari F, Tabarrini O, De Sarro G.
Effects of novel 6-desfluoroquinolones and classic quinolones on
pentylenetetrazole- Domagala JM. Structure-activity and structure-side effect
relationships for the quinolone antibacterials. J Antimicrob Chemother 1994.
170. Donofrio PD, Albers JW. AAEM Minimonograph #34, polyneuropathy:
classification by nerve conduction studies and electromyography. Muscle
Nerve. 1990.
171. Giardina WJ. Assessment of temafloxacin neurotoxicity in rodents. Am J
Med. 1991;91:42S-44S.
172. Halliwell RF, Davey PG, Lambert JJ. Antagonism of GABA-A receptors by 4-
quinolones. J Antimicrob Chemother. 1993;31:457-462.
173. Hori S, Kawamura M. Different effect of anti-inflammatory drugs on
quinolone-induced convulsions. A comparative study on enhancing activity of
anti-inflammatory drugs on quinolone-induced convulsions [abstr]. In:
Program and abstracts of the 40th interscience conference on antimicrobial
agents and chemotherapy, Toronto, Ontario, Canada, September, 2000.
174. Hughes RAC. Peripheral neuropathy. BMJ. 2002.
175. Kamei C, Sugimoto Y, Ohishi H, Okumura Y, Kitazumi K. Epileptogenic
activity induced by combined treatment with antiinflammatory drugs and
enoxacin and its inhibition by a calcium antagonist, nicardipine. Methods
Findings Exp Clin Pharmacol 1996;18:579-88.
176. Kamali F, Ashton CH, Marsh VR, Cox J. Assessment of the effects of
combination therapy with ciprofloxacin and fenbufen on the central nervous
systems of healthy volunteers by quantitative electroencephalography.
Antimicrob Agents Chemother 1998;42:1256-8.
177. Kissel JT. Autoantibody testing in the evaluation of peripheral neuropathy.
Semin Neurol 1998;18:83-94
178. Lacomis D. Small-fiber neuropathy. Muscle Nerve. 2002;26:173-188.
179. Lindenbaum Y, Kissel JT, Mendell JR. Treatment approaches for Guillain-
Barré syndrome and chronic inflammatory demyelinating
polyradiculoneuropathy. Neurol Clin. 2001;19:187-204.
180. Mandema JW, Tukker E, Danhof M. Pharmacokinetic-pharmacodynamic
modeling of the EEG effects of midazolam in individual rats: influence of rate
and route of administration. Br J Pharmacol 1991; 102: 663-8.
181. McManis PG, Schmelzer JD, Zollman PJ, et al. Blood flow and autoregulation
in somatic and autonomic ganglia. Comparison with sciatic nerve. Brain
Scheld WM. Quinolone therapy for infections of the central nervous system.
Rev Infect Dis 1989; 11 Suppl 5: S1194-202.
182. Pourmand R. Evaluating patients with suspected peripheral neuropathy: do
the right thing, not everything. Muscle Nerve. 2002;26:288-290.
183. Puechal X, Said G, Hilliquin P, et al. Peripheral neuropathy with necrotizing
vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of
thirty-two patients. Arthritis Rheum 1995;38:1618-
184. Qian YS, Lu J, Fan WZ, Huang ZS, Chen Y. Epilepsy induced by norfloxacin
in various-week-old rats. Chin J New Drugs Clin Remedies 1998; 17:72-4.
185. Simpson KJ, Brodie MJ. Convulsions related to enoxacin. Lancet 1985.
186. Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U. Possible
interaction of fluoroquinolones with the benzodiazepine-GABAA-receptor
complex. Br J Clin Grant IA, Hunder GG, Homburger HA, et al. Peripheral
neuropathy associated with sicca complex. Neurology 1997;48:855-862
187. Somer T, Finegold SM. Vasculitides associated with infections, immunization,
and antimicrobial drugs. Clin Infect Dis 1995;20:1010-1036
188. Schmuck G, Schurmann A, Schluter G. Determinaton of the excitatory
potencies of fluoroquinolones in the central nervous system by an in vitro
model. Antimicrob Agents Chemother. 1998;42:1831-1836.
189. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic
acquired demyelinating polyneuropathies. Muscle Nerve. 2001;24:311-324.
190. Schwartz MT, Calvert JF. Potential neurologic toxicity related to ciprofloxacin.
DICP. 1990;24:138-140.
191. Segev S, Rehavi M, Rubinstein E. Quinolones, theophylline, and diclofenac
interactions with the gamma-aminobutyric acid receptor. Antimicrob Agents
Chemother. 1988;32:1624-1626.
192. Shintani S, Kusunoki A, Hosoki E, et al. Drug interaction of OPC-17116, a
new quinolone antibacterial agent with nonsteroidal antiinflammatory drugs in
experimental animals [abstr]. In: Program and abstracts of the 31st
interscience conference on antimicrobial agents and chemotherapy, Chicago,
September 29-October 2, 1991.
193. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy.
Neurology. 2000;55:915-920.
194. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy
associated with impaired glucose tolerance. Muscle Nerve. 2001.
195. Thiel R, Metzer S, Gericke C, Rahm U, Stahlmann R. Effects of
fluoroquinolones on the locomotor activity in rats. Arch Toxicol 2001; 75:
196. Tsuji A, Sato H, Kume Y, Tamai I, Okezaki E, Nagata O, et al. Inhibitory
effects of quinolone antibacterial agents on aminobutyric acid binding to
receptors sites in rat brain membrances. Antimicrob Agents Chemother 1988.
197. Wallace KL. Antibiotic-induced convulsions. Crit Care Clin. 1997
198. Wolfe GI, Barohn RJ. Cryptogenic sensory and sensorimotor
polyneuropathies. Semin Neurol. 1998;18:105-111.
199. Allon M, Lopez EJ, Min KW. Acute renal failure due to ciprofloxacin. Arch
Intern Med 1990;150:2187-9.
200. Amitrano L, Gigliotti T, Guardascione MA, Ascione A. Enoxacin acute liver
injury [letter]. J Hepatol 1992;15:270.
201. Antimicrobial-Associated Acute Hepatitis. from Medscape Pharmacotherapy.
Susan C. Nicholson, M.D., C. Douglas Webb, Ph.D., and Robert C.
Moellering, Jr., M.D.
202. Lopez-Navidad A, Domingo P, Cadafalch J, Farrerons J. Norfloxacin-induced
hepatotoxicity. J Hepatol 1990;11:277-8.
203. Blum A. Ofloxacin-induced acute severe hepatitis [letter]. South Med J
1991;84:1158.
204. Levinson JR, Kumar A. Ciprofloxacin-induced cholestatic jaundice: a case
report [letter]. Am J Gastroenterol 1993;88:1619.
205. Microsomal metabolism of ciprofloxacin generates free radicals. Gurbay A,
Gonthier B, Daveloose D, Favier A, Hincal F. Hacettepe University, Faculty of
Pharmacy, Department of Pharmaceutical Toxicology, Ankara, Turkey.
Gatifloxacin-associated acute hepatitis. Pharmacotherapy 2001
Dec;21(12):1579-82 (ISSN: 0277-0008) Henann NE; Zambie MF College of
Pharmacy University of Louisiana at Monroe, and St. Francis Medical Center,
71209, USA.
206. Possible Gatifloxacin-Induced Fulminant Hepatic Failure The Annals of
Pharmacotherapy: Vol. 35, No. 10, pp. 1194–1198. Craig I Coleman, Jeffrey
V pencer, Jenny O Chung, and Prabashni Reddy.
207. Sherman O, Beizer JL. Possible ciprofloxacin-induced acute cholestatic
jaundice. Ann Pharmacother 1994;28:1162-4.
208. Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
29/32
De Sarro A, De Sarro G. Istituto di Farmacologia, Facolta di Medicina e
Chirurgia, Universita di Messina, Policlinico Universitario, Via Consolare
Valeria, Messina, 98125, Italia.
209. Adverse effects of fluoroquinolones. Shimada J, Hori S. Division of Clinical
Pharmacology, St. Marianna University School of Medicine, Kawasaki,
Japan.
210. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on
newer agents. Clin Infect Dis 1999;28:352-64.
211. Stahlmann R. and Lode H.Toxicity of quinolones. Drugs, 1999, vol. 58, no.
S2, pp. 37-42(6) . Institute of Clinical Pharmacology and Toxicology,
Department of Toxicology, University Medical Center Benjamin Franklin,
Freie Universitat Berlin, Germany.
212. Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother
1990;26(suppl D):31-44.
213. Tolerability of fluoroquinolone antibiotics. Past, present and future. Ball P,
Tillotson G. Infectious Diseases Unit, Victoria Hospital, Kirkcaldy, Fife,
Scotland.
214. The safety profile of the fluoroquinolones. Clin Ther. 2000;22:798-817.
Bertino J Jr, Fish D.
215. Quinolone antimicrobial agents. Hooper DC, Wolfson JS. Adverse effects. In:
Hooper DC, Wolfson JS, 2nd ed. Washington, DC: American Society for
Microbiology, 1993.
216. Petition to Require a Warning on All Fluoroquinolone Antibiotics (HRG
Publication #1399). August 1, 1996 . David A. Kessler, M.D., J.D.
Commissioner, Food and Drug Administration 5600 Fishers Lane. Based on
more than 130 reports of tendon inflammation (many involving rupture),
217. Pharmacokinetic interactions related to the chemical structures of
fluoroquinolones. J Antimicrob Chemother. 1996;37(suppl A):41-55. Mizuki Y,
Fujiwara I, Yamaguchi T.
218. Suh B, Lorber B. Quinolones. Med Clin North Am 1995;79:869-94.
219. Norrby SR, Lietman PS. Safety and tolerability of fluoroquinolones. Drugs
1993;45(suppl 3):59-64.
220. Lietman PS. Fluoroquinolone toxicities: an update. Drugs 1995.
221. Quinolones: a practical review of clinical uses, dosing considerations, and
drug interactions. J Family Pract 1996;42:69-78. Borcherding SM, Stevens R,
Nicholas RA, Corley CR, Self T.
222. Adverse drug reactions to fluoroquinolones at a tertiary care hospital in
northern India. Uppal R, Jhaj R, Malhotra S. Department of Pharmacology,
PGIMER, Chandigarh-160 012.Shimada J, Hori S. Adverse effects of
fluoroquinolones.Division of Clinical Pharmacology, St. Marianna University
School of Medicine, Kawasaki, Japan.
223. Rubinstein E. History of quinolones and their side effects. Chemotherapy
2001. Department of Internal Medicine and Unit of Infectious Diseases, Tel
Aviv University School of Medicine, Tel Aviv, Israel.
224. Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam
Physician 2002 . University Wyoming School Pharmacy, Casper, USA.
225. Takayama S, Hirohashi M, Kato M, Shimada H. Toxicity of quinolone
antimicrobial agents. J Toxicol Environ Health 1995; 45: 1-45.
226. Acieri G, August R, Becker N, et al. Clinical experience with ciprofloxacin in
the U.S.A. Eur J Clin Microbiol 1986;5:220-5.
227. Adam D, von Rosenstiel N. Adverse reactions to quinolones, potential
toxicities, drug interactions, and metabolic effects. Infect Dis Clin Pract
1994:S177-84.
228. Adverse effects of fluoroquinolones. Halkin et al (Rev Infect Dis 1988
229. Adverse reactions during clinical trials and post marketing surveillance.
Janknegt et al (Pharm Weekbl Sci 1989 11(4) 124-127)
230. Altes J, Gasco J, de Antonio J, Salas A, Villalonga C. Ciprofloxacin and
delirium [letter]. Ann Intern Med 1989;110:170-1.
231. Arico M, Bossi G, Caselli D, et al. Long-term magnetic resonance survey of
cartilage damage in leukemic children treated with fluoroquinolones. Pediatr
Infect Dis J 1995;14:713-14.
232. Acieri GM, Becker N, Esposito B, et al. Safety of intra-venous ciprofloxacin. A
review. Am J Med 1989;87(suppl 5A):92S-7.
233. Balfour JAB, Wiseman LR. Moxifloxacin. Drugs 1999;57:363-73
234. Ball P, Tillotson G. Tolerability of fluoroquinolone anti-biotics: past, present
and future. Drug Saf 1995;13:343-58.
235. Ball P. Ciprofloxacin: an overview of adverse experiences. J Antimicrob
Chemother 1986;18(suppl D):187-93.
236. Bayer Corp. Cipro (ciprofloxacin) package insert. CT; 1999.
237. Bayer Corp. Avelox (moxifloxacin) package insert., CT; 1999.
238. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95
cases. Clin Infect Dis 1994; 18:946-50.
239. Bristol-Myers Squibb Co. Tequin (gatifloxacin) package insert. Princeton, NJ;
2000.
240. Brighty KE, Gootz TD. The chemistry and biologic profile of trovafloxacin. J
Antimicrob Chemother 1997;39(suppl B):1-14.
241. Chien SC, Wong FA, Fowler CL, et al. Double-blind evaluation of the safety
and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram
doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother
1998.
242. Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of
levofloxacin following once-daily 500-milligram oral or intravenous doses.
Antimicrob Agents Chemother 1997;41:2256-60.
243. Beckmann J, Elsaesser W, Gundert-Remy U, Hertrampf R. Enoxacin: a
potent inhibitor of theophylline metabolism. Eur J Clin Pharmacol 1987.
244. Benign intracranial hypertension after ciprofloxacin administration. 1: Arch
Dis Child 1990 Oct;65(10):1165-1166. Winrow AP, Supramaniam G.
Department of Paediatrics, *Watford General. Hospital, Herts.
245. Breen J, Skuba K, Grasela. D. Safety and tolerability of gatifloxacin, an
advanced-generation, 8-methoxy fluoro-quinolone. J Respir Dis 1999.
246. Bryskier A, Chantot JF. Classification and structure-activity relationships of
fluoroquinolones. Drugs 1995;49(suppl 2):16-28.
247. Callegan MC, Jensen H, Kane ST, Cochran DC. Comparative antibacterial
activity of gatifloxacin and moxifloxacin against ocular isolates. Paper
presented at: The ASCRS/ASOA Symposium on Cataract, IOL and
Refractive Surgery; 2003; San Francisco, CA.
248. Chan PC, Cheng IK, Chan MK, Wong WT. Clinical experience with pefloxacin
in patients with urinary tract infections. Br J Clin Pract 1990;
249. Chodosh S, Lakshminarayan S, Swarz H, Breisch S. Efficacy and safety of a
10-day course of 400 or 600 milligrams of grepafloxacin once daily for
treatment Cutler NR, Vincent J, Jhee SS, et al.
250. Choo P, Ganz NM. Reversible leukopenia related to ciprofloxacin therapy
[letter]. South Med J 1990;83:597.
251. Christ W, Esch B. Adverse reactions to fluoroquinolones in adults and
children. Infect Dis Clin Pract 1994;3(suppl 3):S168-76.
252. Chysky V, Kapila K, Hullman R, et al. Safety of ciprofloxacin in children:
worldwide clinical experience based on compassionate use: emphasis on
joint evaluation. Infection 1991;4:289-96.
253. Ciprofloxacin an update on clinical experience. Areieri et al (Am J of Med
1987)
254. Ciprofloxacin and tenosynovitis. McEwan et al ( Lancet 1988 15 900)
255. Cipro [package insert]. West Haven, Conn: Bayer Corporation; 2002.
256. Cutaneous adverse reaction to ciprofloxacin: demonstration of specific
lymphocyte proliferation and cross-reactivity to ofloxacin in vitro. Ronnau AC,
Sachs B, von Schmiedeberg S, Hunzelmann N, Ruzicka T, Gleichmann E,
Schuppe HC. Infectious Disease Research, Ortho-McNeil Pharmaceutical
Inc, Raritan, NJ 08869-0602, USA.
257. Davey P, McDonald T. Postmarketing surveillance of quinolones, 1990-1992.
Drugs 1993;45(suppl 3):46-53.
258. Davis R, Markham A, Balfour JA. Ciprofloxacin: an updated review of its
pharmacology, therapeutic efficacy and tolerability. Drugs 1996;51:1019-74.
259. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity,
pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
260. DeAbate CA, Henry D, Bensch G, et al. Sparfloxacin vs ofloxacin in the
treatment of acute bacterial exacerbations of chronic bronchitis: a
multicenter, double-blind, randomized, comparative study. Sparfloxacin
multicenter ABECB study group. Chest 1998;114:120-30.
261. DeAbate CA, Fogarty C, Grooms E, et al. Efficacy and safety of gatifloxacin
acute exacerbation of chronic bronchitis (AECB) [abstr]. In: Program and
abstracts of the Infectious Disease Society of America 36th annual meeting,
Denver, CO, November 12-15, 1998.
262. Domagala JM. Structure-activity and structure-side effect relationships for the
quinolone antibacterials. J Antimicrob Chemother 1994;33:685-706.
263. Donnenfeld E, Perry H, Greenman H, et al. Ocular tolerability of the fourthgeneration
fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5%. Poster
presented at: The ARVO Annual Meeting; 2004; Fort Lauderdale, FL.
264. Drago F, Arditti MR, Rebora A. Henoch-Schönlein purpura induced by
fluoroquinolones [letter]. Br J Dermatol 1994;131:448.
265. Evans RE, Bucci FA. A comparison of immediate postop aqueous cultures in
phaco patients receiving gatifloxacin and moxifloxacin preoperatively. Poster
presented at: The ARVO Annual Meeting; April 28, 2004; Fort Lauderdale,
FL.

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
30/32
266. Floxin [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.;
1998.
267. Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study of the
safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in
healthy
268. Garey KW, Amsden GW. Trovafloxacin: an overview. Pharmacotherapy
1999.
269. Gasser TC, Ebert SC, Graversen PH, etal. Pharmacokinetic study of
ciprofloxacin in patients with impaired renal function. Am J Med. 1987
270. Geddes AM. Safety of fleroxacin in clinical trials. Am J Med 1993;94(suppl
3A):201S-3.
271. Farley WJ, Luo LH, Chen LZ, et al. Effects of commercial fourth-generation
fluoroquinolones on corneal epithelial barrier function in experimental murine
dry eye. Poster presented at: The ARVO Annual Meeting 2004.
272. Fish DN. Fluoroquinolone adverse effects and drug interactions.
Pharmacotherapy. 2001;21(10S):253S-272S.
273. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin
Pharmacokinet 1997;32:101-19.
274. Fogarty C, McAdoo M, Paster RZ, et al. Gatifloxacin vs clarithromycin in the
management of acute sinusitis. J Respir Dis 1999;20(suppl):S17-
275. Fogarty CM, Williams J, Haverstock D, et al. Efficacy and safety of
moxifloxacin vs. clarithromycin in the treatment of community-acquired
pneumonia. Program and abstracts of the 39th interscience conference on
antimicrobial agents and chemotherapy, San Francisco, 1999.
276. Forsgren A, Bredberg A, Riesbeck K. New quinolones: in-vitro effects as a
potential source of clinical toxicity. Rev Infect Dis 1989;11(suppl 5):S1382-9.
277. Glaxo Wellcome. Raxar (grepafloxacin) package insert. Research Triangle
Park, NC; 1997.
278. Glaxo Wellcome. Press release: Glaxo Wellcome voluntarily withdraws Raxar
(grepafloxacin). Research Triangle Park, NC; October 1999.
279. Goldstein EJC. Possible role for the new fluoroquinolones (levofloxacin,
grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the
treatment of anaerobic infections: review of current information on efficacy
and safety. Clin Infect Dis 1996;23(suppl 1):S25-30.
280. Goehler K, Stahlberg HJ, Guillaume M, et al. Safety, tolerance and food
effect after single and multiple oral doses of gatifloxacin (GTX), a new
fluoroquinolone antibiotic, to healthy Caucasian volunteers [abstr]. In:
Program and abstracts of the 37th interscience conference on antimicrobial
agents and chemotherapy, Toronto, Ontario, Canada, 1997.
281. Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone.
Clin Infect Dis.2000;31(suppl):S51-S58.
282. Gao J, Siemasko KF, Vu C, et al. Effect of the 4th generation fluoroquinolone
on rabbit corneal wound healing. Poster presented at: The ARVO Annual
Meeting; April 29, 2004; Fort Lauderdale, FL.
283. Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study of the
safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in
healthy adult men. Pharmacotherapy. 2000;20(suppl):49S-58S.
284. Goehler K, Stahlberg HJ, Guillaume M, et al. Safety, tolerance and food
effect after single and multiple oral doses of gatifloxacin (GTX), a new
fluoroquinolone antibiotic, to healthy Caucasian volunteers [abstr]. In:
Program and abstracts of the 37th interscience conference on antimicrobial
agents and chemotherapy, Toronto, Ontario, Canada, 1997.
285. Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases
induced by exogenous agents. J Am Acad Dermatol 1995;33:551-71.
286. Gootz TD, Barrett JF, Sutcliffe JA. Inhibitory effects of quinolone antibacterial
agents on eucaryotic topoisomerases and related test systems. Antimicrob
Agents Chemother 1990;34:8-12.
287. Hoshino K, Sato K, Une T, Osada Y. Inhibitory effects of quinolones on DNA
gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.
Antimicrob Agents Chemother 1989;33:1816-18.
288. Hampel B, Hullman R, Schmidt K. Ciprofloxacin in pediatrics: world-wide
clinical experience based on compassionate use: safety report. Pediatr Infect
Dis J 1997..
289. Henry D. Sparfloxacin multicenter study group. Treatment of acute bacterial
maxillary sinusitis with sparfloxacin and clarithromycin [abstr]. In: Program
and abstracts of the 36th interscience conference on antimicrobial agents
and chemotherapy, New Orleans, LA, September 15-18, 1996.
290. Henry D, Ellison W, Sullivan J, et al. Treatment of community-acquired acute
uncomplicated urinary tract infection with sparfloxacin versus ofloxacin.
Antimicrob Agents Chemother 1998.
291. Heyd A, Haverstock D. Retrospective analysis of the safety profile of oral and
intravenous ciprofloxacin in a geriatric population. Clin Ther 2000.
292. Holland ML, Chien SC, Corrado ML, et al. The pharmacokinetic profile of
levofloxacin following once- or twice-daily 500 mg oral administration of
levofloxacin Levaquin [package insert]. Raritan, NJ: Ortho-McNeil
Pharmaceutical, Inc.; 2002.
293. Idiopathic intracranial hypertension after ofloxacin treatment. Acta Neurol
Scand 1993 Jun;87(6):503-4. Getenet JC, Croisile B, Vighetto A,
Grochowicki M, Goudable B, Aimard G, Trillet M. Neurology Service,
Neurological Hospital, Lyon, France.
294. Imrie K, Gold W, Salit I, Keating A. Ciprofloxacin-induced neutropenia and
erythema multiforme [letter]. Am J Hematol 1993;43:159-60.
295. Iravani A. Efficacy of lomefloxacin as compared to norfloxacin in the
treatment of uncomplicated urinary tract infections in adults. Am J Med
1992;92(suppl 4A):75S-81.
296. Jick SS, Jick H, Dean AD. A follow-up safety study of ciprofloxacin users.
Pharmacotherapy 1993;13:461-4.
297. Jungst G, Mohr R. Side effects of ofloxacin in clinical trials and in
postmarketing surveillance. Drugs 1987;34(suppl 1):144-9.
298. Kawada Y, Kumamoto Y, Aso Y. Dose finding study on levofloxacin in
complicated urinary tract infections. Chemotherapy 1992;40
299. Kubin R, Reiter C. Safety update of moxifloxacin: a current review of clinical
trials and post-marketing observational studies [abstr]. In: Program and
abstracts of the 40th interscience conference on antimicrobial agents and
chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000.
300. Kusajima H, Manita S, Yamamoto T, et al. Phototoxicity and photochemical
generation of reactive oxygen by new quinolones [abstr]. In: Program and
abstracts of the 38th interscience conference on antimicrobial agents and
chemotherapy, San Diego, September 24-27, 1998.
301. Lacreta F, Kollia G, Duncan G, et al. Effect of a high-fat meal on the
bioavailability of gatifloxacin in healthy volunteers [abstr]. In: Program and
abstracts of the 38th interscience conference on antimicrobial agents and
chemotherapy, San Diego, September 24-27, 1998.
302. LeBel M, Teng R, Dogolo LC, et al. The effect of steady-state trovafloxacin
on the steady-state pharmacokinetics of caffeine in healthy subjects [abstr].
In: Program and abstracts of the 36th interscience conference on
antimicrobial agents and chemotherapy, New Orleans, LA, 1996.
303. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on
newer agents. Clin Infect Dis. 1999;28:352-364.
304. Lipsky BA, Miller B, Schwartz R, et al. Sparfloxacin versus ciprofloxacin for
the treatment of community-acquired, complicated skin and skin-structure
infections. Clin Ther 1999;21:675-90.
305. Lipsky BA, Dorr MB, Magner DJ, et al. Safety profile of sparfloxacin in North
American phase III clinical trials [abstr]. In: Program and abstracts of the 36th
interscience conference on antimicrobial agents and chemotherapy, New
Orleans, LA, September 15-18, 1996.
306. Lumpkin MM. United States Food and Drug Administration public health
advisory: Trovan (trovafloxacin/alatrofloxacin) [letter]. 1999.
307. Neringer R, Forsgren A, Hansson C. Lomefloxacin versus norfloxacin in the
treatment of uncomplicated urinary tract infections: three-day versus sevenday
treatment. Scand J Infect Dis 1992;24:773-80.
308. Nord CE. Effect of quinolones on the human intestinal microflora. Drugs
1995.
309. Noroxin [package insert]. WestPoint, Pa: Merck& Company, Inc.; 1999.
310. North DS, Fish DN, Redington JJ. Levofloxacin, a second-generation
fluoroquinolone. Pharmacotherapy 1998;18:915-35.
311. Man I, Murphy J, Ferguson J. Fluoroquinolone photo-toxicity: a comparison
of moxifloxacin and lomefloxacin in normal volunteers. J Antimicrob
Chemother 1999;43(suppl B):77-82.
312. Marchbanks CR. Drug-drug interactions with fluoroquinolones.
Pharmacotherapy 1993;13(Pt 2):23S-8.
313. Matsumoto S, Way W, Tarlo K, Short B. Comparative toxicity of
fluoroquinolone antibiotics on corneal cells in vitro. Cornea. In press.
314. Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to
the chemical structure of the fluoroquinolones. J Antimicrob Chemother 1996.
315. McGarvey WC, Singh D, Trevino SG. Partial Achilles tendon ruptures
associated with fluoroquinolone antibiotics: a case report and literature
review. Foot Ankle Int 1996;17:496-8.
316. Osheroff N, Elsea SH, Nitiss JL. Cytotoxicity of quinolones toward eukaryotic
cells. J Biol Chem 1992;267:13150-3.

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
31/32
317. Monk JP, Campoli-Richards DM. Ofloxacin: a review of its antibacterial
activity, pharmacokinetic properties and therapeutic use. Drugs 1987.
318. Norrby SR. Side effects of quinolones: comparisons between quinolones and
other antibiotics. Eur J Clin Microbiol Infect Dis 1991;10:378-83.
319. Okimoto N, Niki Y, Soejima R. Effect of levofloxacin on serum concentration
of theophylline. Chemotherapy 1992;40(suppl 3):68-74.
320. Ortho-McNeil Pharmaceutical. Levaquin (levofloxacin) package insert.
Raritan, NJ; 2000.
321. Ortho-McNeil Pharmaceutical. Floxin (ofloxacin) package insert. Raritan, NJ;
1997.
322. Pace GL, Gatt P. Fatal vasculitis associated with ofloxacin [letter]. Br Med J
1989;299:658.
323. Paton JH, Reeves DS. Adverse reactions to fluoroquinolones. Adverse Drug
Reaction Bull 1992;153:575-8.
324. Peloquin CA. Quinolones and tuberculosis [letter]. Ann Pharmacother 1996.
325. Pierfitte C, Gillet P, Royer RJ. More on fluoroquinolone antibiotics and tendon
rupture [letter]. N Engl J Med 1995;332:193.
326. Price MO, Price FW. Effect of gatifloxacin ophthalmic solution 0.3% on
corneal endothelial cell counts in normal subjects and in cataract surgery
patients. Poster presented at: The ARVO Annual Meeting; April 29, 2004;
Fort Lauderdale, FL.
327. Pfizer, Inc. Trovan (trovafloxacin) package insert. New York, NY; 1998.
328. Polk RE, Healy DP, Sahai J, Drwal L, Racht E. Effect of ferrous sulfate and
multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.
Antimicrob Agents Chemother 1989;33:1841-4.
329. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J
Antimicrob Chemother 1999;43(suppl B): von Keutz E, Schluter G.
330. Qiao HL, Zhang LR, Guo YZ, Gao N, Zhang QT, Liu FZ, et al. Study on the
pharmacokinetics and relative bioavaila-bilities of levofloxacins in health
volunteers. Chin Hosp Pharm J 2000; 20: 396-8.
331. Qu JW, Lang YM, Li YQ, Liu JM. Study on pharmacokinetics of norfloxacin
infusion preparation. Chin J Mod Appl Pharm 1994; 11: 19-20. 1997
332. Radandt JM, Marchbanks CR, Dudley MN. Interactions of fluoroquinolones
with other drugs: mechanisms, variability, clinical significance, and
management. Clin Infect Dis 1992;14:272-84.
333. Rhône-Poulenc Rorer Pharmaceuticals. Zagam (sparfloxacin) package
insert. Collegeville, PA; 1996.
334. RANDALL J. OLSON, MD. Fluoroquinolones:Clinical Implications.The effect
of gatifloxacin and moxifloxacin on corneal wound healing.
335. Reeves RR. Ciprofloxacin-induced psychosis. Ann Pharmacother 1992.
336. Retrospective analysis of the safety profile of oral and intravenous
ciprofloxacin in a geriatric population. Heyd A, Haverstock D. Bayer
Corporation, Pharmaceutical Division, Connecticut 06516, USA.
337. Rizk E. The US clinical experience with lomefloxacin, a new once-daily
fluoroquinolone. Am J Med 1992;92(suppl 4A):130S-5.
338. Saito A, Irabu Y, Fukuhura H. Dose finding comparative study on levofloxacin
in chronic urinary tract infections. Chemotherapy 1992.
339. Saito A, Soejima R. The first comparative study with levofloxacin: a doubleblind
comparative study of gatifloxacin, a new quinolone, and levofloxacin in
pneumonia [abstr]. In: Program and abstracts of the 38th interscience
conference on antimicrobial agents and chemotherapy, San Diego, 1998.
340. Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and
efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment
of acute bacterial sinusitis in adults. Respir Med 2000;94:
341. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmaco-kinetics, safety, and
tolerability of ascending single doses of moxifloxacin, a new 8-methoxy
quinolone, administered to healthy subjects. Antimicrob Agents Chemother
1998.
342. Segev S, Yaniv I, Haverstock D, Reinhart H. Safety of long-term therapy with
ciprofloxacin: data analysis of controlled clinical trials and review. Clin Infect
Dis 1999.
343. Soejima R, Kawane H, Okimoto N. Comparative study of levofloxacin and
ofloxacin in bacterial pneumonia by the double-blind method. Chemotherapy
1992.
344. Safety of the new fluoroquinolones compared with ciprofloxacin. Ball P.
345. Schentag JJ, Scully BE. Antimicrobial therapy and vaccines. In: Yu VL,
Merigan TC Jr, Barriere SL, eds. Quinolones. Baltimore: Williams & Wilkins,
1999.
346. Springklee M. Safety and tolerability profile of moxifloxacin (MXF) [abstr]. In:
Proceedings of the 9th European congress on chemotherapy, microbiology
and infectious diseases, Berlin, May 21-24, 1999.
347. Stahlmann R, Lode H. Toxicity of quinolones. Drugs. 1999;58.
348. Stass H, Dalhoff A, Kubitza D. BAY 12-8039: study on the food effect after
oral administration of 200 mg SD to healthy volunteers [abstr]. In:
Proceedings of the 8th European congress on chemotherapy, microbiology
and infectious diseases, Lausanne, Switzerland, May 16-19, 1998.
349. Stille W, Harder S, Mieke S, et al. Decrease of caffeine elimination in man
during co-administration of 4-quinolones. J Antimicrob Chemother 1987.
350. Stass H, Kubitza D. Study to assess the interaction between BAY 12-8039
and dairy products in healthy volunteers [abstr]. In: Proceedings of the 9th
European congress on chemotherapy, microbiology and infectious diseases,
Berlin, May 21-24, 1999.
351. Stein GE. Pharmacokinetics and pharmacodynamics of newer
fluoroquinolones. Clin Infect Dis 1996;23(suppl 1):S19-24.
352. Suto MJ, Domagala JM, Roland GE, Mailloux GB, Cohen MA.
Fluoroquinolones: relationships between structural variations, mammalian
cell cytotoxicity, and Szarfman A, Chen M, Blum MD. More on
fluoroquinolone antibiotics and tendon rupture. N Engl J Med 1995.
353. Teng R, Liston TE, Harris SC. Multiple-dose pharmaco-kinetics and safety of
trovafloxacin in healthy volunteers. J Antimicrob Chemother 1996;37:955-63.
354. Tequin [package insert]. NJ: Bristol-Myers Squibb Company; 2002.
355. Thorsteinsson SB, Bergan T, Rohwedder R. Tolerance of intravenously
administered ciprofloxacin. Chemotherapy 1988;34:256-60.
356. Van Der Linden PD, Sturkenboom MCJ, Herings RMC, et al. A population
based study of quinolones and the risk of Achilles tendon rupture [abstr]. In:
Program and abstracts of the 40th interscience conference on antimicrobial
agents and chemotherapy, Toronto, Ontario, Canada, 2000.
357. Vohr HW, Wasinska-Kempka G, Ahr HJ. Studies on the phototoxic potential
of a new 8-methoxy-quinolone: BAY 12-8039 [abstr]. In: Program and
abstracts of the 36th interscience conference on antimicrobial agents and
chemotherapy, New Orleans, LA, September 15-18, 1996.
358. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared
with 7 day clarithromycin therapy for the treatment of acute exacerbations of
chronic bronchitis. J Antimicrob Chemother 1999;44:501-13.
359. Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. Am J Med
1991;9(suppl 6A):153S-61.
360. Zhanel GG, Ennis K, Vercaigne L, Gin AS, Embil J, Hoban DJ. Critical review
of fluoroquinolones: focus on respiratory infections. Drugs 2002;
361. Baker SE, Hang Hangi MC. Possible gatifloxacin-induced hypoglycemia. Ann
Pharmacother. 2002;36:1722-1726.
362. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the
pharmacology of the endocrine pancreas. In: Hardman JG, Limbird LE,
Molinoff PB, et al, eds. Goodman & Gilman’s the Pharmacological Basis of
Therapeutics. 9th ed. New York: McGraw-Hill; 1996: 1487-1517.
363. Fish DN. Fluoroquinolone adverse effects and drug interactions.
Pharmacotherapy. 2001;21(10S):253S-272S.
364. Fraser AG, Harrower AD. Convulsions and hyperglycaemia associated with
nalidixic acid. Br Med J. 1977;2(6101):1518-1518.
365. Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or
ciprofloxacin on glucose homeostasis and insulin production in patients with
non-insulin dependent diabetes mellitus maintained with diet and exercise.
Pharmacotherapy. 2000;20(suppl):76S-86S.
366. GraselaDM, LaCreta FP, Kollia GD, et al. Lack of effect ofmultiple-dose
gatifloxacin (GAT) on oral glucose tolerance (OGTT), glucose and insulin
homeostasis, and glyburide pharmacokinetics (PK) in type II non-insulin
dependent diabetes mellitus(NIDDM) [abstract]. In: Proceedings and
Abstracts of the 39th Interscience Conference on Antimicrobial Agents and
Chemotherapy. Washington, DC: American Society forMicrobiology; 1999.
367. Jick SS, Jick H, Dean AD. A follow-up safety study of ciprofloxacin users.
Pharmacotherapy. 1993;13(5):461-464.
368. Lefébvre PJ, Scheen AJ. Hypoglycemia. In: Porte D, Sherwin RS, eds.
Ellenberg & Rifkin’s Diabetes Mellitus. 5th ed. Stamford, Conn: Appleton &
Lange; 1997:1307-1328.
369. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat
pancreas islets by quinolone antibiotics. Br J Pharmacol. 1996
370. Menzies DJ, Dorsainvil PA, Dunha BA, et al. Severe and persistent
hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.
Am J Med. 2002;113:232-234.
371. Parilo MA. Gatifloxacin-associated hypoglycemia. J Pharm Technol. 2002.
372. Roberge RJ, Kaplan R, Frank R, et al. Glyburide-ciprofloxacin interaction with
resistant hypoglycemia. Ann Emerg Med. 2000

QUINOLONE ANTIBIOTICS TOXICITY. Dec 2003
32/32
373. WhitelyM, Worlding J, Patel S, et al. Hypoglycemia in a diabetic patient,
associate with ciprofloxacin therapy [case report]. Pract Diabetes. 1993.